ES2326460B1 - QUATERNARY AMMONIUM SALTS OF SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICINES. - Google Patents

Abstract

Quaternary ammonium salts of compounds of substituted pyrazoline, its preparation and use as medicines.

The present invention relates to salts of quaternary ammonium of substituted pyrazoline compounds, methods for its preparation, medicines comprising these compounds, in addition to its use for the preparation of a medicine for Treatment of humans and animals.

Description

Quaternary ammonium salts of compounds of substituted pyrazoline, its preparation and use as medicines.

Field of the Invention

The present invention relates to salts of quaternary ammonium of substituted pyrazoline compounds, methods for its preparation, medicines comprising these compounds, in addition to their use for the preparation of a medicine for the treatment of humans and animals.

Background of the invention

Cannabinoids are compounds that are derived from the Cannabis sativa plant that is commonly known as marijuana. The most active chemical compound of natural cannabinoids is tetrahydrocannabinol (THC), particularly Δ9 -THC.

These natural cannabinoids, in addition to their synthetic analogs, enhance their physiological effects through of binding to specific G-protein coupled receptors, the called cannabinoid receptors.

Currently, they have been identified and cloned two different types of receptors that bind both to natural cannabinoids as synthetic. These receivers, which are designated CB_ {1} and CB_ {2}, participate in a variety of physiological or pathophysiological processes in humans and animals, for example, system related processes central nervous, the immune system, the cardiovascular system, the endocrine system, the respiratory system, the tract gastrointestinal or with reproduction, as described by example, in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana / Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds., CRC Press, 1992.

Therefore, compounds that have a high binding affinity for these cannabinoid receptors and that are suitable for modulating these receptors are useful in prevention and / or the treatment of disorders related to recipients of cannabinoids

In particular, the CB_ {1} receiver participates in many different disorders related to ingestion of foods, such as bulimia or obesity, including obesity associated with type II diabetes (non-insulin dependent diabetes) and therefore, suitable compounds can be used to regulate this receptor in the prophylaxis and / or treatment of these disorders.

Description of the invention

An object of the present invention was provide novel compounds for use as principles Medication assets In particular, these active ingredients must be suitable for the modulation of the receptors of cannabinoids, more particularly for the modulation of cannabinoid 1 receptors (CB1).

This object was achieved by providing the quaternary ammonium salts of substituted pyrazoline compounds  of general formula I given below, its stereoisomers, corresponding salts and corresponding solvates thereof.

It has been found that these compounds have a high affinity for cannabinoid receptors, particularly for the CB1 receptor, and acting as modulators, by example, antagonists, inverse agonists or agonists of these receivers Therefore, they are suitable for prophylaxis and / or treatment of various system related disorders central nervous, immune system, system cardiovascular, endocrine system, respiratory system, gastrointestinal tract or with reproduction in humans and / or animals, preferably in humans including infants, Children and seniors.

Therefore, in one of its aspects this invention relates to quaternary ammonium salts of compounds of substituted pyrazoline of general formula I,

one

in the that

X is O or S;

A represents a hydrogen atom or a radical unsubstituted or at least monosubstituted alkyl;

R1 and R2, independently of each other, they represent in each case an aryl or heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted;

or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be linked with a bridge by at least one unsubstituted alkylene group or at less monosubstituted;

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted;

a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which contains optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted;

an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a system cyclic mono or polycyclic, unsubstituted or at least monosubstituted and / or it can be linked through an alkylene group, a group alkenylene or an alkynylene group, unsubstituted or at least monosubstituted;

a moiety -O-R 7; a rest -S-R 8; a moiety -NH-R9 or a moiety -NR 10 R 11;

R 5 and R 6, independently of each other, they represent in each case a hydrogen atom;

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted;

or

R 5 and R 6 together with the atom of bridging nitrogen form a heterocyclic ring not substituted or at least monosubstituted, saturated or unsaturated, which may contain at least one additional heteroatom as a member of ring and / or that may be condensed with one or two systems monocyclic or polycyclic, optionally at least monosubstituted;

R 7, R 8, R 9, R 10 and R 11 independently of each other, they represent in each case a radical saturated or unsaturated aliphatic, unsubstituted or at least monosubstituted,

or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted;

an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a system cyclic mono or polycyclic, unsubstituted or at least monosubstituted and / or it can be linked through an alkylene group, a group alkenylene or an alkynylene group, unsubstituted or at least monosubstituted;

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or unsubstituted naphthoate or at least monosubstituted, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

2

Y

R 12 and R 13, independently between yes, they represent in each case a saturated aliphatic radical or unsaturated, unsubstituted or at least monosubstituted;

an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which can be linked through a group  alkylene, unsubstituted or at least monosubstituted;

or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which can be linked to a bridge by at least one group alkylene unsubstituted or at least monosubstituted and / or may be bound through an unsubstituted alkylene group or at least monosubstituted;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

If one or more of the residues R 1 to R 13 and B represents or comprises an aryl, heteroaryl, benzoate radical or naphthoate, which may be substituted, unless defined contrary, preferably said aryl radical, heteroaryl, benzoate or naphthoate may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of perfluoroalkyl C 1-6, -C 1-6 alkyl substituted with one or more methoxy and / or ethoxy, -alkyl groups C 1-6, -C 1-6 alkyl substituted with one or more hydroxyl groups, -alkyl C 1-6 substituted with one or more chlorine atoms, -O-C 1-6 alkyl, -O-C 1-6 alkyl substituted with one or more methoxy and / or ethoxy groups, -S-alkyl C 1-6, -C (= O) -OH, -C (= O) -O-alkyl C_ {1-6}, -O-C (= O) -alkyl C 1-6, F, Cl, Br, I, -CN, -OCF 3, -O-C 2 F 5, -O-C 3 F 7, -O-C_ {4} F_ {9}, -SCF_ {3}, -SCF_ {3}, -SCF 2 H, -SCFH 2, -OH, -SH, -SO 3 H, -NH-C (= O) -alkyl C 1-6, -N (alkyl C 1-6) - C (= O) -alkyl C_ {1-6}, -NO_ {2}, -CHO, -C (= O) -C 1-6 alkyl, -C (= O) -C 1-6 perfluoroalkyl, -C (= S) -NH-alkyl C 1-6, -CF 2 H, -CFH 2, -C (= O) -NR A R B, -C (= O) -NH-NR C R D, -S (= O) -C 1-6 alkyl, -S (= O) 2 -alkyl C_ {1-6}, -S (= O) 2 -phenyl, - (alkylene C_ 1-5) - S-alkyl C_ {1-6}, - (rent C_ {1-5}) - S (= O) -alkyl C_ {1-6}, - (rent C 1-5) - S (= O) 2 -alkyl C 1-6, NR E R F, - (alkylene C 1-5) - NR E R F, -S (= O) -NH2, -S (= O) 2 -NH-alkyl C_ {1-6}, -S (= O) 2 -NH-phenyl, -NH-S (= O) 2 -alkyl C 1-6, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl;

in which in each case the cyclic remains cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl they can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of  group consisting of F, Cl, Br, I, -OH, -CF 3, -CN, -NO 2,  -C 1-6 alkyl, -O-alkyl C_ {1-6}, -O-CF 3 and -S-CF_ {3} and

in which R A, R B, R E and R F, independently of each other, they represent hydrogen or -alkyl C 1-6 or R A and R B in each case together with the nitrogen atom that bridges form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more alkyl radicals C_ {1-6} identical or different

and in which R C and R D, independently of each other, they represent hydrogen, -alkyl C_ {1-6}, -C (= O) -O-alkyl C 1-16, C 3-6 cycloalkyl, - (C 1-5 alkylene) - cycloalkyl C 3-6, - (alkylene C 1-6) - O-alkyl C 1-6 or C 1-6 alkyl substituted with one or more hydroxyl groups or R C and R D in each case together with the nitrogen atom that acts as a bridge form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more selected substituents regardless of the group consisting of -alkyl C 1-6, -C (= O) -alkyl C_ {1-6}, -C (= O) -O-alkyl C_ {1-6}, -C (= O) -NH-alkyl C_ {1-6}, -C (= S) -NH-alkyl C 1-6, oxo (= O), alkyl C_ {1-6} substituted with one or more groups hydroxyl, - (alkylene C 1-6) - O-alkyl C_ {1-6} and -C (= O) -NH_ {2}.

More preferably said aryl and heteroaryl radicals may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of -CF 3, -C 2 F 5 , -C 3 F 7, -C 4 F 9, -CH 2 Cl, -CHCl 2, -C 2 H 4 Cl, methyl, ethyl, n -propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -CH 2 -OH, -CH 2 -CH 2 - OH, -CH 2 -CH 2 -CH 2 -OH, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O- CH 3, -O-CH 2 -O-C 2 H 5,
-C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH_ { 2} -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, -C (= O) -OH,
-C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C 3 H 7, -C (= O) -OC (CH 3) 3, -OC (= O) -CH 3, -OC (= O) -C 2 H 5, -OC ( = O) -CH (CH 3) 2, -OC (= O) -CH 2 -CH 2 -CH 3, -OC (= O) -C (CH 3 }) 3, F, Cl, Br, I, -CN, -OCF 3, -O-C 2 F 5, -O-C 3 F 7, -O -C_ {F} {{9}},
-SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -SO 3 H, -NH-C (= O) -CH 3, -NH-C (= O) -C 2 H 5, -NH-C (= O) -C (CH 3) 3, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -CF_ { 3}, -C (= O) -C 2 F 5, -C (= O) -C 3 F 7, -C (= S) -NH-CH 3, - C (= S) -NH-C2H5, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH -CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -C (= O) -NH-NH-CH 3, -C (= O) -NH-NH-C2H5, -C (= O) -NH-NH2, -C (= O) -NH-N (CH3) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, - S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -S (= O) 2 -phenyl, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3 ) 2, -N (C 2 H 5) 2, -CH 2 -N (CH 3) 2, - (CH 2) - morpholinyl, - (CH 2) -piperidinyl, - (CH 2) -piperazinyl, - (CH 2) -N (C 2 H 5) 2, -CH 2 -N (C 3 H 7) 2, -CH 2 -N (C 4 H 9) 2, -CH 2 -N (CH_ { 3}) (C 2 H 5), -S (= O) -NH 2, -S (= O) 2 -NH-CH 3, -S (= O) 2 -NH-phenyl, -NH-S (= O ) 2 -CH 3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl, wherein said thiophenyl radical may be substituted with 1, 2 or 3 substituent (s) selected (s) independently from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl.

Preferred aryl radicals that are optionally at least monosubstituted are phenyl and naphthyl (1- and 2-naphthyl).

Preferably the heteroatoms that are present as ring members in the heteroaryl radical can,  unless otherwise defined, select regardless of the group consisting of nitrogen, oxygen and sulfur. More preferably a heteroaryl radical is from 5 to 14 members and may comprise 1, 2, 3 or 4 selected heteroatoms regardless of the group consisting of nitrogen, oxygen and sulfur.

Preferred heteroaryl radicals that are not substituted or at least monosubstituted are pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3] thiadiazolyl, [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, imidazo [2,1-b] thiazolyl, 2H-Chromenyl, pyranyl, indazolyl and quinazolinyl.

Preferred aryl and heteroaryl radicals that are condensed with a mono or polycyclic cyclic system are [1,3] -benzodioxolyl, [1,4] -benzodioxanyl, [1,2,3,4] -tetrahydronaphthyl, (2,3) -dihydro-1H-cyclopenta [b] indolyl, [1,2,3,4] -tetrahydroquinolinyl, [1,2,3,4] -tetrahydroisoquinolinyl, [1,2,3,4] -tetrahydroquinazolinyl and [3,4] -dihydro-2H-benzo [1,4] oxazinyl.

If one or more of the residues R 1 to R 13 and B represents or comprises a saturated cycloaliphatic radical or unsaturated, optionally containing at least one heteroatom as  ring member, preferably a cycloaliphatic radical C_ {1-18}, which may be substituted, unless the opposite is defined, preferably said radical cycloaliphatic may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), perfluoroalkyl C 1-6, -C 1-6 alkyl, C 1-6 alkyl substituted with one or more groups hydroxyl, -C 1-6 alkyl substituted with one or more chlorine atoms, substituted C 1-6 alkyl with one or more methoxy and / or ethoxy groups, -O-C 1-6 alkyl, -O-C 1-6 alkyl substituted with one or more methoxy and / or ethoxy groups, -S-alkyl C 1-6, -C (= O) -OH, -C (= O) -O-alkyl C_ {1-6}, -O-C (= O) -alkyl C 1-6, F, Cl, Br, I, -CN, -OCF 3, -O-C 2 F 5, -O-C 3 F 7, -O-C4 {F9}, -SCF_3, -SCF2H, -SCFH2, -OH, -SH, -SO3H, -NH-C (= O) -alkyl C 1-6, -N (alkyl C 1-6) - C (= O) -alkyl C_ {1-6}, -NO_ {2}, -CHO, -C (= O) -C 1-6 alkyl, -C (= O) -C 1-6 perfluoroalkyl, - (= S) -NH-alkyl C 1-6, -CF 2 H, -CFH 2, -C (= O) -NR A R B, -C (= O) -NH-NR C R D, -S (= O) -C 1-6 alkyl, -S (= O) 2 -alkyl C_ {1-6}, -S (= O) 2 -phenyl, - (alkylene C_ 1-5) - S-alkyl C 1-6, - (alkylene C_ {1-6} -S (= O) -alkyl C 1-6, - (alkylene C 1-5) - S (= O) 2 -alkyl C 1-6, -NR E R F, - (alkylene C 1-5) - NR E R F, -S (= O) -NH2, -S (= O) 2 -NH-alkyl C_ {1-6}, -S (= O) 2 -NH-phenyl, -NH-S (= O) 2 -alkyl C 1-16, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl;

in which, in each case, the cyclic remains cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl they can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of group consisting of F, Cl, Br, I, -OH, -CF 3, -CN, -NO 2, -C 1-6 alkyl, -O-alkyl C_ {1-6}, -O-CF 3 and -S-CF_ {3} and

in which R A, R B, R E and R F, independently of each other, they represent hydrogen or -alkyl C 1-6 or R A and R B in each case together with the nitrogen atom that bridges form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more alkyl radicals C_ {1-6} identical or different

and in which R C and R D, independently of each other, they represent hydrogen, -alkyl C_ {1-6}, -C (= O) -O-alkyl C 1-16, C 3-8 cycloalkyl, - (C 1-5 alkylene) - cycloalkyl C 3-8, - (alkylene C 1-6) - O-alkyl C 1-6 or C 1-6 alkyl substituted with one or more hydroxyl groups or R C and R D in each case together with the nitrogen atom that acts as a bridge form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more selected substituents regardless of the group consisting of -alkyl C 1-6, -C (= O) -alkyl C_ {1-6}, -C (O) -O-alkyl C_ {1-6}, -C (= O) -NH-alkyl C_ {1-6}, -C (= S) -NH-alkyl C 1-6, oxo (= O), alkyl C_ {1-6} substituted with one or more groups hydroxyl, - (alkylene C 1-6) - O-alkyl C_ {1-16} and -C (= O) -NH_ {2}.

More preferably said cycloaliphatic radicals may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of oxo (= O), thioxo (= S), -CF 3 , -C_ {F} {5},
-C 3 F 7, -C 4 F 9, -CH 2 Cl, -CHCl 2, -C 2 H 4 Cl, methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -CH2 -OH, -CH2 -CH2 -OH , -CH 2 -CH 2 -CH 2 -OH, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH_ {3}, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH_ {3} (CH 3) 2, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH_ { 3, -O-CH (CH 3) 2,
-O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 } H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 } -CH_ {2} -CH_ {3},
-SC (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H_ {5}, -C (= O) -O-C 3 H 7, -C (= O) -OC (CH 3) 3, -OC (= O) -CH_ { 3}, -OC (= O) -C 2 H 5, -OC (= O) -CH (CH 3) 2, -OC (= O) -CH 2 - CH 2 -CH 3, -OC (= O) -C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -O-C_ {2} F5, -O-C3F7, -O-C4F9, -SCF3, -SCF2H, -SCFH2 , -OH, -SH, -SO 3 H, -NH-C (= O) -CH 3, -NH-C (= O) -C 2 H 5, -NH-C (= O) -C (CH 3) 3, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 H_ {5}, -C (= O) -C (CH 3) 3, -C (= O) -CF 3, -C (= O) -C 2 F 5 , -C (= O) -C 3 F 7, -C (= S) -NH-CH 3, -C (= S) -NH-C 2 H 5, - CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 } H 5, -C (= O) -NH-C 3 H 7,
-C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -C (= O) -NH -NH-CH 3, -C (= O) -NH-NH-C 2 H 5, -C (= O) -NH-NH 2, -C (= O) -NH -N (CH 3) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5, -S (= O) -C_ { 3} H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) _ {2} -C 3 H 7, -S (= O) 2 -phenyl, -NH 2, -NH-CH 3, -NH-C 2 H 5 , -N (CH 3) 2, -N (C 2 H 5) 2, -CH 2 -N (CH 3) 2, - (CH2) -morpholinyl, - (CH2) -piperidinyl, - (CH2) -piperazinyl, - (CH2) -N (C2H5) _ {2}, -CH 2 -N (C 3 H 7) 2, -CH 2 -N (C 4 H 9) 2, -CH_ {2} -N (CH 3) (C 2 H 5), -S (= O) -NH 2, -S (= O) 2 -NH-CH 3 , -S (= O) 2 -NH-phenyl, -NH-S (= O) 2 -CH 3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl , phenoxy and benzyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl.

If one or more of the residues R 1 to R 13 and B represents or comprises a cycloaliphatic radical, preferably a C 3-16 cycloaliphatic radical, which contains one or more heteroatoms as ring members, a Unless otherwise defined, each of these heteroatoms may preferably be selected from the group consisting of nitrogen, oxygen and sulfur. More preferably a cycloaliphatic group may optionally contain 1, 2, 3 or 4 heteroatom (s)
selected (s) independently of the group consisting of N, O and S as ring members.

Saturated cycloaliphatic radicals or unsaturated, optionally containing at least one heteroatom as suitable ring member can be selected preferably from the group consisting of cyclopropyl, cyclobutyl,  cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclrideridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydrofuranyl, (2,5) -dihydrothiophenyl, (2,3) -dihydrofuranyl, (2,3) -dihydrofuranyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4) -dihydro-2H-pyranyl, (3,4) -dihydro-2H-thiopyranyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl,  oxazolidinyl, (1,3) -dioxanyl, (1,4) -dioxanyl and (1,3) -dioxolanyl.

Saturated cycloaliphatic radicals or unsaturated, optionally containing at least one heteroatom as suitable ring member that are condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted may preferably be selected from the group that consists of indolinyl, isoindolinyl, decahydronaphthyl, (1,2,3,4) -tetrahydroquinolinyl, (1,2,3,4) -tetrahydroisoquinolinyl, (1,2,3,4) -tetrahydronaphthyl, octahydro-cyclopenta [c] pyrrolyl, (1,3,4,7,9a) -hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a) -hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7) -dihydro-4H-thieno [3,2-c] pyridinyl, (2,3) -dihydro-1H-benzo [de] isoquinolinyl and (1,2,3,4) -tetrahydroquinoxazolinyl.

Preferably, a cycloaliphatic radical, a C 3-16 cycloalkyl radical, a radical C 4-16 cycloalkenyl, a radical C 4-16 heterocycloalkyl or a radical C 5-16 heterocycloalkenyl may be attached with a bridge using 1, 2 or 3 unsubstituted alkylene groups or At least monosubstituted.

Saturated cycloaliphatic radicals or suitable unsaturated, optionally containing at least one heteroatom as a ring member that are joined by a bridge by at least one alkylene group, unsubstituted or at least monosubstituted, can preferably be selected from the group that consists of adamantyl, bicyclo [2.2.1] heptyl, bicyclo [3.1.1] heptyl, norbornenyl and 8-aza-bicyclo [3.2.1] octyl.

A mono or polycyclic cyclic system according to the present invention, if not defined otherwise, means a mono or polycyclic hydrocarbon cyclic system, preferably a mono or bicyclic cyclic system, which can be saturated, unsaturated or aromatic Each of its different rings can show a different degree of saturation, that is, they can be saturated, unsaturated or aromatic. Optionally each of the mono or bicyclic cyclic system rings may contain one or more, preferably 1, 2 or 3, heteroatom (s) as ring member (s), which may be identical or different and which can preferably be selected from the group consisting in nitrogen, oxygen and sulfur. The rings of the cyclic system mono or bicyclic are preferably 5, 6 or 7 members.

The term "condensate" according to the present invention means that a ring or cyclic system is attached to another ring or cyclic system, in which the terms "voided" or "anelated" are also used by experts  in the art to designate this kind of union.

If one or more of the residues R 1 to R 11 comprises a mono or polycyclic cyclic system, which may be substituted, unless otherwise defined, preferably said mono or polycyclic cyclic system may be optionally substituted. with 1, 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of oxo (= O), thioxo (= S), perfluoroC 1-6 alkyl, -C 1- alkyl 6, C 1-6 alkyl substituted with one or more hydroxyl groups, -C 1-6 alkyl substituted with one or more chlorine atoms, -C 1-6 alkyl substituted with one or more methoxy groups and / or ethoxy, -O-C 1-6 alkyl, -O-C 1-6 alkyl substituted with one or more methoxy and / or ethoxy groups, -S-C 1-6 alkyl, - C (= O) -OH, -C (= O) -O-C 1-6 alkyl, -OC (= O) -C 1-6 alkyl, F, Cl, Br, I, -CN , -OCF_3, -O-C2F5, -O-C3F7, -O-C4F9, -SCF3, - SCF 2 H, -SCFH 2, -OH, -SH, -SO 3 H, -NH-C (= O) -C 1-6 alkyl, -N (C 1- alkyl) 6}) - C (= O) -C 1-6 alkyl, -NO 2, -CHO, -C (= O) -C 1-6 alkyl, -C (= O) -C 1-6 perfluoroalkyl, -C (= S) -NH-C 1-6 alkyl, -CF_ { 2 H, -CFH 2, -C (= O) -NR A R B, -C (= O) -NH-NR C R D, -S (= O) -C 1-6 alkyl, -S (= O) 2 -C 1-6 alkyl, -S (= O) 2 -phenyl, - (C_ alkylene 1-5) - S-C 1-6 alkyl, - (C 1-5 alkylene) - S (= O) -C 1-6 alkyl, - (C 1-5 alkylene) ) -S (= O) 2 -C 1-6 alkyl, -NR E R F, _ (C 1-5 alkylene) - NR E R ^ {F}, -S (= O) -NH2, -S (= O) 2 -
NH-C 1-6 alkyl, -S (= O) 2 -NH-phenyl, -NH-S (= O) 2 -C 1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl;

in which, in each case, the cyclic remains cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl they can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of F, Cl, Br, I, -OH, -CF3, -CN, -NO 2, -C 1-6 alkyl, -O-C 1-6 alkyl, -O-CF 3 and -S-CF 3 and

in which R A, R B, R E and R F, independently of each other, they represent hydrogen or -alkyl C 1-6 or R A and R B in each case together with the nitrogen atom that bridges form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more alkyl radicals C_ {1-6} identical or different

and in which R C and R D, independently of each other, they represent hydrogen, -alkyl C_ {1-6}, -C (= O) -O-alkyl C 1-6, C 3-8 cycloalkyl, - (C 1-5 alkylene) - cycloalkyl C 3-8, - (alkylene C 1-6) - O-alkyl C 1-6 or C 1-6 alkyl substituted with one or more hydroxyl groups or R C and R D in each case together with the nitrogen atom that acts as a bridge form a radical selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, thiomorpholinyl, morpholinyl, azepanyl and diazepanyl that may be at least monosubstituted with one or more selected substituents regardless of the group consisting of -alkyl C 1-6, -C (= O) -alkyl C_ {1-6}, -C (= O) -O-alkyl C_ {1-6}, -C (= O) -NH-alkyl C_ {1-6}, -C (= S) -NH-alkyl C 1-6, oxo (= O), alkyl C_ {1-6} substituted with one or more groups hydroxyl, - (alkylene C 1-6) - O-alkyl C_ {1-6} and -C (= O) -NH_ {2}.

More preferably said mono or polycyclic cyclic system may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of oxo (= O), thioxo (= S), -CF_ {3},
-C 2 F 5, -C 3 F 7, -C 4 F 9, -CH 2 Cl, -CHCl 2, -C 2 H 4} Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -CH2 -OH, -CH_ {2} -CH2 -OH, -CH2 -CH2 -CH2 -OH, -O-CH2 -O-CH3, -O-CH2 } -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) ) 2, -C (OCH 3) (CH 3) 2, -O-CH 3, -O-C 2 H 5, -O-CH_ { 2} -CH 2 -CH 3, -O-CH (CH 3) 2,
-O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 } H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 } -CH 2 -CH 3, -SC (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C 3 H 7, -C (= O) -OC (CH 3) _ { 3}, -OC (= O) -CH 3, -OC (= O) -C 2 H 5, -OC (= O) -CH (CH 3) 2, -OC (= O) -CH 2 -CH 2 -CH 3, -OC (= O) -C (CH 3) 3, F, Cl, Br, I, - CN, -OCF 3, -O-C 2 F 5, -O-C 3 F 7, -O-C 4 F 9, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -SO 3 H, -NH-C (= O) -CH 3, -NH-C (= O) -C_ {2 H 5, -NH-C (= O) -C (CH 3) 3, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -CF 3, -C ( = O) -C_ {2} F_ {5}, -C (= O) -C_ {F} {7}, -C (= S) -NH-CH_ {3}, -C (= S) - NH-C 2 H 5, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7,
-C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -C (= O) -NH -NH-CH 3, -C (= O) -NH-NH-C 2 H 5, -C (= O) -NH-NH 2, -C (= O) -NH -N (CH 3) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5, -S (= O) -C_ { 3} H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) - C 3 H 7, -S (= O) 2 -phenyl, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CH 2 -N (CH 3) 2, - (CH_ { 2) - morpholinyl, - (CH 2) -piperidinyl, - (CH 2) -piperazinyl, - (CH 2) -N (C 2 H 5) 2, -CH 2 -N (C 3 H 7) 2, -CH 2 -N (C 4 H 9) 2, -CH 2 - N (CH 3) (C 2 H 5), -S (= O) -NH 2, -S (= O) 2 -NH-CH 3, -S (= O) 2 -NH-phenyl, -NH-S (= O) 2 -CH 3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, phenyl, thiophenyl, phenoxy and benzyl , wherein said thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl.

If one or more of the residues R 3 to R 13, A and B represent or comprise a saturated aliphatic radical or unsaturated, unsubstituted or at least monosubstituted, preferably a C 1-16 aliphatic radical, said aliphatic radical can be linear or branched.

Preferably said aliphatic radicals, to Unless otherwise defined, they may be substituted optionally with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents independently selected from the group consisting of -OH, F, Cl, Br, I, -O-C 1-6 alkyl, -OCF 3, -O-C 2 F 5, -O-C 3 F 7, -O-C 4 F 9, -CF 3, -C 2 F 5, -C 3 F 7, -C 4 F 9, -NH 2, -NH-C 1-6 alkyl, -N (C 1-6 alkyl) 2, -C (= O) -OH, -C (= O) -O-alkyl C_ {1-6}, -C (= O) -NH2, -C (= O) -NH-alkyl C 1-6, -C (= O) -N (alkyl C 1-6) 2, -CN, -NO 2, -S (= O) -NH2, -CHO, -C (= O) -C 1-6 alkyl, -S (= O) -C 1-6 alkyl, -S (= O) 2 -alkyl C_ {1-6}, -NH-S (= O) -alkyl C_ {1-6}, -NH-C (= O) -O-alkyl C_ {1-5} and -NH-C (= O) -alkyl C_ {1-16}.

More preferably said aliphatic radicals they can be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents independently selected from the group that consists of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN, -NO 2, -NH-C (= O) -CH 3, -NH-C (= O) -C 2 H 5, -NH-C (= O) -C (CH 3) 3, -NH-C (= O) -O-CH 3, -NH-C (= O) -O-C 2 H 5, -NH-C (= O) -O-C (CH 3) 3, -C (= O) - NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C (CH 3) 3, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5 and -C (= O) -C (CH 3) 3.

Suitable alkyl radicals, preferably C 1-16 alkyl radicals, are selected from group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl, 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl and n-hexadecyl.

Suitable at least monosubstituted alkyl radicals are selected from the group consisting of -CF 3, -CH 2 F, -CF 2 H, -CH 2 -O-CH 3, -C 2 } F 5, -CH 2 -CH 2 -F, -CH 2 -CN, -CH 2 -OH, -CH 2 -CH 2 -CN, -CH_ {2} -CH2 -OH, -CH2 -CH2 -OCH3,
-CH_ {2} -CH_ {2} -CH_ {-} -CN, -CH_ {2} -CH_ {2} -CH_ {2} -OH, -CH_ {2} -CH_ {2} -CH_ {2 } -O-CH 3, -CH 2 -CH 2 -CH 2 -CH 2 -O-CH 3, -CH 2 -NH 2, -CH_ {2} -N (CH 3) 2, -CH 2 -N (C 2 H 5) 2, -CH 2 -CH-NH 2 , -CH 2 -CH 2 -N (CH 3) 2, -CH 2 -CH 2 -N (C 2 H 5) 2 , -CH 2 -CH 2 -CH 2 -NH 2, -CH 2 -CH 2 -CH 2 -N (CH 3) 2 and -CH 2 -CH 2 -CH 2 -N (C 2 H 5) 2.

An alkenyl radical according to the present invention  It comprises at least one carbon-carbon double bond.  Suitable alkenyl radicals, preferably alkenyl radicals C_ {2-16}, are selected from the group consisting of  vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, n-heptenyl, n-octenyl, n-nonenyl, n-decenyl, n-undecenyl, n-dodecenyl, n-tridecenyl, n-tetradecenyl, n-pentadecenyl and n-hexadecenyl.

An alkynyl radical comprises at least one triple carbon-carbon bond. Alkynyl radicals suitable, preferably alkynyl radicals C_ {2-16}, are selected from the group consisting of ethynyl, propynyl, n-butynyl, n-pentinyl, n-hexinyl, n-octinyl, n-noninyl, n-decinyl, n-undecinyl, n-dodecinyl, n-tridecinyl, n-tetradecinyl, n-pentadecinyl and n-hexadecinyl.

If any of the substituents represents a  alkylene group, an alkenylene group or an alkynylene group, which may be substituted, said alkylene group, alkenylene group or alkynylene group may, if not defined otherwise, not be substituted or substituted by one or more substituents, preferably not substituted or substituted with 1, 2 or 3 substituent (s). Said substituent (s) preferably it can be independently selected from the group consisting of -O-alkyl C 1-6, -S-alkyl C_ {1-5}, -F, Cl, Br, I, -CN, -CF_ {3}, -OCF 3, -SCF 3, -OH, -SH, -SO 3 H, -NH 2, -NH (C 1-6 alkyl), -N (alkyl C 1-6) 2 and phenyl. Plus preferably said substituent (s) can be selected from the group consisting of -F, Cl, Br, I, -CN, -CF 3, -OCF 3, -SCF 3, -OH, -SH, -SO 3 H, -NH 2, -NH-CH 3, -N (CH 3) 2, -O-CH 3 and -O-C 2 H 5. An alkenylene group comprises at least one carbon-carbon double bond, a group alkynylene comprises at least one triple bond carbon-carbon

Preferred alkylene groups, preferably  C 1-5 alkylene groups, include - (CH 2) -, -CH (CH 3) -, -CH (phenyl), - (CH 2) 2 -, - (CH 2) 3 -, - (CH 2) 4 -, - (CH 2) 5 and - (CH 2) 6 -, suitable alkenylene groups, preferably C 2-5 alkenylene groups, include -CH = CH-, -CH2 -CH = CH- and -CH = CH-CH2 - and suitable alkynylene groups, preferably C 2-5 alkynylene groups -, include -C \ equivC-, -CH_ {2} -C \ equivC- and -C \ equivC-CH_ {2} -.

Quaternary ammonium salts of substituted pyrazoline compounds of general formula I provided previously, in which

X is O or S;

A represents a hydrogen atom or a radical C 1-10 alkyl unsubstituted or at least monosubstituted;

R1 and R2, independently of each other, they represent in each case an aryl radical of 6 or 10 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted;

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a C 1-16 alkyl radical, a C 2-16 alkenyl radical or a radical C 2-16 alkynyl unsubstituted or at least monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or that can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted,  and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted;

an aryl radical of 6 or 10 members, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

a moiety -O-R 7; a remainder-S-R 8; a rest -NH-R 9 or a moiety -NR 10 R 11;

R 5 and R 6, independently of each other, they represent in each case a hydrogen atom;

a C 1-16 alkyl radical, C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

or

R 5 and R 6 together with the bridging nitrogen atom form an unsubstituted or at least monosubstituted, saturated or unsaturated 4 to 10 membered heterocyclic ring, which may optionally contain 1, 2 or 3 heteroatus-
additional mo (s) selected from the group consisting of sulfur, nitrogen and oxygen as ring member (s) and / or that may be condensed with one or two monocyclic or polycyclic cyclic systems, optionally at least monosubstituted ;

R 7, R 8, R 9, R 10 and R 11, independently of each other, they represent in each case

a C 1-6 alkyl radical no substituted or at least monosubstituted, alkenyl radical C 2-16 or alkynyl radical C 2-16;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted, and / or that can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C_ {5-16}, unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted, and / or that can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

an aryl radical of 6 or 10 members, not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted, and / or that can be joined by a group C 1-5 alkylene, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

or a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted and / or that can be joined by a group C 1-5 alkylene, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or unsubstituted naphthoate or at least monosubstituted, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

       \ vskip1.000000 \ baselineskip
    

3

       \ vskip1.000000 \ baselineskip
    

Y

R 12 and R 13, independently between yes, they represent in each case

a C 1-6 alkyl radical, a C 2-16 alkenyl radical or an alkynyl radical C_ {2-16}, unsubstituted or at least monosubstituted;

an aryl radical of 6 or 10 members not substituted or at least monosubstituted, which may be attached to through a C 1-5 alkylene group no substituted or at least monosubstituted;

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be attached to through a C 1-5 alkylene group, a group C 2-5 alkenylene or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which can be linked in each case through an alkylene group C_ {1-5} unsubstituted or at least monosubstituted and / or can be linked by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

or a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which in each case can be linked through an alkylene group C_ {1-5} unsubstituted or at least monosubstituted and / or can be linked by a bridge by at least one alkylene group C_ {1-5} unsubstituted or at least monosubstituted;

in which

the rings of the cyclic system mentioned previously they are, in each case independently of each other, of 5, 6 or 7 members and may, in each case independently of each other, optionally contain 1, 2 or 3 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur;

the heteroaryl radicals mentioned previously, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected regardless of group consisting of nitrogen, oxygen and sulfur as ring member (s);

heterocycloalkyl radicals and radicals heterocycloalkenyl mentioned above, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur as ring member (s);

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

Preference is also given to ammonium salts quaternary of substituted pyrazoline compounds of formula general I, in which A represents a monovalent oxygen anion (O -) or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be  optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, -CN and -NO2;

and R 1 to R 13, X and B have the meaning given above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

       \ vskip1.000000 \ baselineskip
    

Therefore, ammonium salts are preferred. quaternary of substituted pyrazoline compounds of formula general I provided above, wherein R 1 and R 2, independently of each other, they represent in each case a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3] thiadiazolyl, [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl e imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of  group consisting of -CF 3, -CH 2 -Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, phenoxy and thiophenyl, in the that said thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group that It consists of F, Cl, Br, methyl, ethyl and n-propyl;

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl , aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydrofuranyl, (2,5) -dihydrothiophenyl, (2,3) -hydrofuranyl, (2,3) -dihydrofuranyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4) -dihydro-2H-pyranyl, (3,4) -dihydro -2H-thiopyranyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl , (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3) -dioxanyl, (1,4) -dio xanyl, (1,3) -dioxolanyl, decahydronaphthyl, octahydro-cyclopenta [c] pyrrolyl, decahydroquinolinyl and dodecahydro-carbazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl , 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3,
-O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3 , -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) _ {2}, -S-CH2 -CH2 -CH2 -CH3, -SC (CH3) 3, F, Cl, Br, I, -CN , -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO, -C (= O) -CH_ { 3},
-C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, - (= O) -NH- C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2 , -S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O ) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -
C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

and R 3 to R 13, X, A and B have the meaning given above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

Preference is also given to ammonium salts quaternary of substituted pyrazoline compounds of formula general I, wherein R 3 and R 4, independently between yes, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n- hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected independently from the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O -C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2,
-N (C 2 H 5) 2, -CN and -NO 2;

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, indolyl which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) - (CH 2) - ( CH 2) - or -CH = CH and / or which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl , ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH_ { 3) 3, F, Cl, Br, I,
-CN, -OCF_3, -SCF_3, -SCF2H, -SCFH2, -OH, -SH, -NO2, -CHO, -C (= O) - CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH_ { 2}, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C ( = O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) })_{2},
-S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) )_{2};

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) ) - (CH2) - (CH2) - or -CH = CH and / or which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2 -pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH ( CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH_ {3}, -S-C2H5, -S-CH2 -CH2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) ) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH,
-NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C_ {H2}, -C (= O) -C (CH_ {3} ) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O ) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -
CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2 , -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2 ;

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11;

and R 1, R 2, R 5 to R 13, X, A and B have the meaning given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

       \ vskip1.000000 \ baselineskip
    

Ammonium salts are also preferred. quaternary of substituted pyrazoline compounds of formula general I provided above, in which R 5 and R 6, independently of each other, they represent in each case an atom of hydrogen;

or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n -hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1 , 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 - CH 2 -CH 3,
-O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3 , -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) _ {2}, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, -CN and -NO 2;

and R 1 to R 4, R 7 to R 13, X, A and B have the meaning given above, optionally in form of one of its stereoisomers, preferably enantiomers or  diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

Preference is also given to ammonium salts quaternary of substituted pyrazoline compounds of formula general I, in which R 5 and R 6 together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, indolinyl, isoindolinyl, (1,2,3,4) -tetrahydroquinolinyl, (1,2,3,4) -tetrahydroisoquinolinyl, octahydro-cyclopenta [c] pyrrolyl, (1,3,4,7,9a) -hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a) -hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7) -dihydro-4H-thieno [3,2-c] pyridinyl, (2,3) -dihydro-1H-benzo [de] isoquinolinyl and (1,2,3,4) -tetrahydroquinoxazolinyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;

and R 1 to R 4, R 7 to R 13, X, A and B have the meaning given above, optionally in form of one of its stereoisomers, preferably enantiomers or  diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

Quaternary ammonium salts of substituted pyrazoline compounds of the general formula I provided above are also preferred, wherein R 7, R 8, R 9, R 10 and R 11} independently of each other, in each case they represent a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4- octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) - octyl; 2- (6-methyl) -octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s)
selected (s) independently from the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH_ {2} -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC ( CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, - N (C 2 H 5) 2, -CN and -NO 2;

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo [3.2.1] octyl and diazepanyl, which may be linked through a group - (CH 2) -, - (CH 2) - (CH_) {2} - - - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3 ) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF_ { 2} H, -SCFH2,
-OH, -SH, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) - C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3 , -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) ) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C_ { 2} H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 - C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyloyl isool , which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) - (CH 2) - (CH 2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl , ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O- CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 } -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I,
-CN, -OCF_3, -SCF_3, -SCF2H, -SCFH2, -OH, -SH, -NO2, -CHO, -C (= O) - CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH_ { 2}, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C ( = O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) })_{2},
-S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) )_{2};

and R 1 to R 6, R 12, R 13, X, A and B have the meaning given above, optionally in form of one of its stereoisomers, preferably enantiomers or  diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

Preference is also given to ammonium salts quaternary of substituted pyrazoline compounds of formula general I, in which B represents an anion selected from the group consisting of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate which may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group that it consists of F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

4

and R 1 to R 13, X and A have the meaning provided above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding of same.

Ammonium salts are also preferred. quaternary of substituted pyrazoline compounds of formula general I provided above, in which R 12 and R 13 independently of each other, they represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl; which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, -NH2, -NH-CH3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, benzimidazolyl, isoquinolinyl and pyrazolyl, which may be linked through a group - (CH2) -, - (CH2) - (CH2 }) - or - (CH2) - (CH2) - (CH2) and / or may be substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O- CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 } H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 } -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF_ {2} H, -SCFH2, -OH, -SH,
-NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C_ {H2}, -C (= O) -C (CH_ {3} ) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O ) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -
CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -SO 3 H, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H_ { 5) 2 and phenyl;

or a radical selected from the group consisting in cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo [2.2.1] heptyl, which may be attached through of a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) and / or may optionally be substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O- CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (-O) -CH_ {3}, -C (= O) C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7 -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

and R 1 to R 11, X, B and A have the meaning given above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof.

Preference is also given to ammonium salts quaternary of substituted pyrazoline compounds of formula general I, in which

X is O or S;

A represents a hydrogen atom a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH2) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 2) 3, -CN and -NO2;

R 1 and R 2, independently of each other, represent in each case a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3], benzo [2,1,3], benzo [2,1,3] [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzoisoxazolyl, benzisothiazolyl and imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected
independently of the group consisting of -CF 3, -CH 2 -Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2- pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH_ {3} 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH_ { 3}, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S -CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3,
F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO , -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF_ {2} H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH3, -C (= O) -NH-C2} H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2,
-C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H_ { 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, - N (CH 3) 2, -N (C 2 H 5) 2, phenoxy and thiophenyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituent ( s) independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl.

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl , aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydrofuranyl, (2,5) -dihydrothiophenyl, (2,3) -hydrofuranyl, (2,3) -dihydrofuranyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4) -dihydro-2H-pyranyl, (3,4) -dihydro -2H-thiopyranyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl , (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3) -dioxanyl, (1,4) -dio xanyl, (1,3) -dioxolanyl, decahydronaphthyl, octahydro-cyclopenta [c] pyrrolyl, decahydroquinolinyl and dodecahydro-carbazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl , 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3,
-O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3 , -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) _ {2}, -S-CH2 -CH2 -CH2 -CH3, -SC (CH3) 3, F, Cl, Br, I, -CN , -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO, -C (= O) -CH_ { 3},
-C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH -C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2 }, -S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S
(= O) 2 -C 3 H 7), -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH_ { 3) 2 and -N (C 2 H 5) 2;

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a radical selected from the group consisting in methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) independently selected from the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN and -NO 2;

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, indolyl which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) - (CH 2) - ( CH 2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H_ {5}, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 - CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S- C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, - SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH , -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH2, -C (= O) -NH-CH3, -C (= O) -NH-C2H5, -C (= O) -NH-C_ {3 H7, -C (= O) -N (CH3) 2, -C (= O) -N (C2H5) 2,
-S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) )_{2};

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) ) - (CH 2) - (CH 2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group that It consists of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2- pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH_ {3} 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH_ { 3}, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3 , -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3 }, F, Cl, Br, I, -CN, -OCF_3, -SCF3, -SCF2H, -SCFH2, -OH, -SH,
-NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C_ {H2}, -C (= O) -C (CH_ {3} ) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O ) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -
CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2 , -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2 ;

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11;

R 5 and R 6, independently of each other, they represent in each case a hydrogen atom;

or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n -hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1 , 2, 3, 4 or 5 substituent (s) selected independently from the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 - CH 2 -CH 3,
-O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3 , -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) _ {2}, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, -CN and -NO 2;

or

R 5 and R 6 together with the bridging nitrogen atom form a moiety selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, (1,2,3,6) -trahydropyridinyl, (1,2,3,4 ) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, indolinyl, isoindolinyl, (1,2,3,4) -tetrahydroquinolinyl, (1,2,3,4) -tetrahydroisoquinolinyl, octahydro-cyclopenta [c] pyrrolyl, (1,3,4,7,9a) - hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a) -hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6.7) -dihydro-4H-thieno [3, 2-c] pyridinyl, (2,3) -dihydro-1H-benzo [de] isoquinolinyl and (1,2,3,4) -tetrahydroquinoxazolinyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s)
selected (s) independently from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert- butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3 }, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) _ { 3}, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C_ { 2} H5,
-C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O- CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 - CH 2 -CH 3, -S-CH
(CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl , Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2,
-CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -OC
(CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) _{2},
-C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H_ { 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, - N (CH 3) 2, -N (C 2 H 5) 2, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;

R 7, R 8, R 9, R 10 and R 11 independently of each other, they represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN and -NO 2;

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bicyclo [3.2.1] octyl and diazepanyl, which may be linked through a group - (CH 2) -, - (CH 2) - (CH_) {2} - - - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3 ) 3, -S-CH 3, -S-C 2 H_ {5}, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 - CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 } H, -SCFH2,
-OH, -SH, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) - C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3 , -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) ) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C_ { 2} H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 - C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyloyl isool , which may be linked through a group - (CH 2) -, - (CH 2) - (CH 2) -, - (CH 2) - (CH 2) - (CH 2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl , ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 } -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I,
-CN, -OCF_3, -SCF_3, -SCF2H, -SCFH2, -OH, -SH, -NO2, -CHO, -C (= O) - CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH_ { 2}, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C ( = O) -NH-C 3 H 7, C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) )_{2},
-S (= O) -CH_ {3}, -S (= O) -C_ {H} {5}, -S (= O) -C_ {3} H_ {7}, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) )_{2};

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate that may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

5

Y

R 12 and R 13, independently between yes, they represent in each case a radical selected from the group that It consists of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl; which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, -NH2, -NH-CH3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, benzoimidazolyl, isoquinolinyl and pyrazolyl, which may be linked through a group - (CH2) -, - (CH2) - (CH2 }) - or - (CH2) - (CH2) - (CH2) and / or may be substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O- CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 } H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 } -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF_ {2} H, -SCFH2, -OH, -SH,
-NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C_ {H2}, -C (= O) -C (CH_ {3} ) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O ) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5 , -S (= O) -C 3 H 7, -S (= O) 2 -
CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -SO 3 H, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H_ { 5) 2 and phenyl;

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and bicyclooctenyl. it can be linked through a group - (CH2) -,
- (CH 2) - (CH 2) -, - (CH 2) - (CH 2) - (CH 2) and / or may be optionally substituted with 1, 2, 3 , 4 or 5 substituent (s)
selected (s) independently from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert- butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3 }, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) _ { 3}, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C_ { 2} H5,
-C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O- CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 - CH 2 -CH 3, -S-CH
(CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl , Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2,
-CHO, -C (= O) -CH 3, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -OC
(CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) _{2 C
(= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 H 5, - S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5 , -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N ( CH 3) 2 and -N (C 2 H 5) 2;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

Ammonium salts are particularly preferred  quaternary of substituted pyrazoline compounds of formula general I provided above, in which

X is O or S;

A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl;

R 1 and R 2, independently of each other, represent in each case a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3], benzo [2,1,3], benzo [2,1,3] [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected
regardless of the group consisting of -CF 3, -CH 2 -Cl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH_ { 2 -CH 3, -O-CH (CH 3) 2,
-O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH2, -OH, -SH, -NO2, -CHO, -CF2H,
-CFH2, phenoxy and thiophenyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl;

R 3 represents H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;

a radical selected from the group consisting in phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be linked through a group - (CH2) and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, F, Cl and Br;

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11;

R 4 represents H or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl;

R 7, R 8, R 9, R 10 and R 11 independently of each other, they represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

R 5 and R 6 together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of

6

7

8

9

10

eleven

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate that may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

12

Y

R 12 and R 13, independently between yes, they represent in each case a radical selected from the group that consists of -CF 3, -C 2 F 5, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl and n-tetradecyl;

a radical selected from the group consisting in phenyl, pyridinyl, pyrazolyl, benzoimidazolyl, isoquinolinyl and naphthyl, which may be substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of  group consisting of F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -OH, -NO 2, -NH 2, phenyl and -SO 3 H;

a radical selected from the group consisting in cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo [2.2.1] heptyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2);

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

More particularly preferred are the salts of quaternary ammonium of substituted pyrazoline compounds of general formula I provided above, in which

X is O;

A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl and n-propyl;

R1 represents a radical selected from group consisting of phenyl and thienyl (thiophenyl), which may be  optionally substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, I, -O-CH 3 and -O-C 2 H 5;

R2 represents a phenyl radical, which can be substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br and I;

R 3 represents H; F; Cl; Br; I; -OH, -CN; -C (= O) -H;

a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;

a benzyl radical or a residue -O-R 7;

R 4 represents H or a selected radical from the group consisting of methyl, ethyl, n-propyl, iso-propyl and n-butyl;

R 5 and R 6 together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of

13

14

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

fifteen

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

R 7 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

in the case that A is not an oxygen anion monovalent, B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, methanesulfonate, ethanesulfonate, toluenesulfonate, benzenesulfonate, (2,5) -dihydroxybenzenesulfonate, naphthalene-2-sulfonate, 5-sulfo-naphthalene-1-sulfonate, cyclamate, dodecane-1-sulfonate and (7.7) -dimethyl-2-oxo-bicyclo [2.2.1] -hept-1-yl-methanesulfonate;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

The most particularly preferred are the salts of quaternary ammonium of substituted pyrazoline compounds of general formula I provided previously selected from the group consisting of

       \ vskip1.000000 \ baselineskip
    

[one]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- piperidinium

[2]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -4-methyl- morpholin-4-io

[3]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- azepanium

[4]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -2-methyl- octahydro-cyclopenta [c] pyrrolium

[5]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[6]

Iodide of (R) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[7]

Iodide of (S) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[8]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-ethyl-piperidinium

[9]

Iodide of (R) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1- ethyl piperidinium

[10]

Iodide of (S) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- ethyl piperidinium

[eleven]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[12]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-iodo-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[13]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[14]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[fifteen]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- azepanium

[16]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[17]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-iodo-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[18]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[19]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-pyrrolidinium

[twenty]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[twenty-one]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[22]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[2. 3]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[24]

Iodide of cis-1 - [[5- (4-bromo-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[25]

Iodide of cis-1 - [[5- (4-fluoro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[26]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[27]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[28]

Iodide of trans-1 - [[5- (4-bromo-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] - amino] -1-methyl-piperidinium

[29]

Iodide of trans-1 - [[5- (4-fluoro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[30]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl azepanium

[31]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl pyrrolidinium

[32]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl pyrrolidinium

       \ newpage
    

[33]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl azepanium

[3. 4]

Iodide of cis-2 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[35]

Iodide of trans-2 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[36]

Iodide of 2 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,4-dimethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[37]

Iodide of 2 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,4-dimethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[38]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-trifluoromethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[39]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methoxy-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[40]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-cyano-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[41]

Iodide of 1 - [[5- (5-Chloro-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[42]

Iodide of 1 - [[5- (5-Bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[43]

Iodide of 1 - [[5- (4-Bromo-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[44]

Iodide of cis-1 - [[5- (5-chloro-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[Four. Five]

Iodide of trans-1 - [[5- (5-chloro-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazole-3-carbo- nil] -amino] -1-methyl-piperidinium

[46]

Iodide of cis-1 - [[5- (5-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[47]

Iodide of trans-1 - [[5- (5-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[48]

Iodide of cis-1 - [[5- (4-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[49]

Iodide of trans-1 - [[5- (4-bromo-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium Y

[fifty]

Iodide of cis-1 - [[5- (4-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-hydroxy-4-methyl-4,5-dihydro-1H-pyrazole- 3-carbonyl] -amino] -1-methyl-piperidinium

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

       \ newpage
    

In another aspect, the present invention provides an N-oxide of general formula Ia,

16

at that

X a is O or S;

R 1a and R 2a, independently between yes, they represent in each case an aryl or heteroaryl radical, no substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted;

or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be linked with a bridge by at least one unsubstituted alkylene group or at less monosubstituted;

R 3a and R 4a, independently between yes, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (O) -H;

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted;

a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which contains optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted;

an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a system cyclic mono or polycyclic, unsubstituted or at least monosubstituted and / or it can be linked through an alkylene group, a group alkenylene or an alkynylene group optionally at least monosubstituted;

a moiety -O-R 7a; a rest -S-R 8a; a moiety -NH-R9a or a moiety -NR 10a R 11a;

R 5a and R 6a, independently between yes, they represent in each case a hydrogen atom;

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted;

or

R 5a and R 6a together with the atom of bridging nitrogen form a heterocyclic ring not substituted or at least monosubstituted, saturated or unsaturated, which may contain at least one additional heteroatom as a member of ring and / or that may be condensed with one or two systems monocyclic or polycyclic, optionally at least monosubstituted;

R 7a, R 8a, R 9a, R 10a and R 11a independently of each other, in each case represent a saturated or unsaturated aliphatic radical, unsubstituted or at least monosubstituted,

or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted;

or an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a group alkylene, an alkenylene group or an alkynylene group, not substituted or at least monosubstituted;

       \ vskip1.000000 \ baselineskip
    

Particularly preferred are N-oxides of general formula I provided above, in which

X a is O or S;

R 1a and R 2a, independently between yes, they represent in each case an aryl radical of 6 or 10 members no substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted;

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

or a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

R 3a and R 4a, independently between yes, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a C 1-16 alkyl radical, a C 2-16 alkenyl radical or a radical C 2-16 alkynyl unsubstituted or at least monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or that can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted;

an aryl radical of 6 or 10 members, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

a moiety -O-R 7a; a residue-S-R 8a; a rest -NH-R 9a or a -NR 10a R 11a moiety;

R 5a and R 6a, independently between yes, they represent in each case a hydrogen atom;

a C 1-16 alkyl radical, C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

or

R 5a and R 6a together with the bridging nitrogen atom form a heterocyclic ring of 4 to 10 unsubstituted or at least substituted, saturated or unsaturated members, which may optionally contain 1, 2 or 3 heteroatom (s)
additional (s) selected from the group consisting of sulfur, nitrogen and oxygen as ring member (s) and / or that may be condensed with one or two monocyclic or polycyclic cyclic systems, optionally at least monosubstituted;

R 7a, R 8a, R 9a, R 10a and R 11a independently of each other, represent in each case

a C 1-6 alkyl radical, a C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or which can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted;

an aryl radical of 6 or 10 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted, and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

or a heteroaryl radical of 5 to 14 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

in which

the rings of the cyclic system mentioned previously they are, in each case independently of each other, of 5, 6 or 7 members and may, in each case independently of each other, optionally contain 1, 2 or 3 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur;

the heteroaryl radicals mentioned previously, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected regardless of group consisting of nitrogen, oxygen and sulfur as ring member (s);

heterocycloalkyl radicals and radicals heterocycloalkenyl mentioned above, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur as ring member (s);

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

More particularly preferred are N-oxides of general formula provided above, in which

X a is O or S;

R 1a and R 2a, independently of each other, represent in each case a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3], benzo [2,1,3], benzo [2,1,3] [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected
regardless of the group consisting of -CF 3, -CH 2 -Cl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH_ { 2 -CH 3, -O-CH (CH 3) 2,
-O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH2, -OH, -SH, -NO2, -CHO, -CF2H,
-CFH2, phenoxy and thiophenyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl;

R 3a represents H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;

a radical selected from the group consisting in phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be linked through a group - (CH2) and / or may be optionally substituted with 1, 2, 3, 4 6 5 substituent (s) selected regardless of the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, F, Cl and Br;

a moiety -O-R 7a; a rest -S-R 8a, a moiety -NH-R 9a or a moiety -NR 10a R 11a;

R 4a represents H or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl;

R 7a, R 8a, R 9a, R 10a and R 11a independently of each other, represent in each case

a radical selected from the group consisting in methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

R 5a and R 6a together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of

17

18

19

twenty

twenty-one

22

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

       \ vskip1.000000 \ baselineskip
    

Even more particularly preferred are N-oxides of the general formula provided above,

in which

X a is O;

R 1a represents a radical selected from the group consisting of phenyl and thienyl (thiophenyl), which may be  optionally substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, I, -O-CH 3 and -O-C 2 H 5;

R2 represents a phenyl radical, which can be substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br and I;

R 3a represents H; F; Cl; Br; I; -OH, -CN; -C (= O) -H;

a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;

a benzyl radical or a residue -O-R 7;

R 4a represents H or a selected radical from the group consisting of methyl, ethyl, n-propyl, iso-propyl and n-butyl;

R 5a and R 6a together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of

2. 3

24

       \ vskip1.000000 \ baselineskip
    

25

and R 7a represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

       \ vskip1.000000 \ baselineskip
    

The most particularly preferred compound is

[51]

N-oxide acid piperidin-1-ylamide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

       \ vskip1.000000 \ baselineskip
    

The compounds of general formula Ia can Obtained by methods well known to experts in the matter.

In another aspect, the present invention also provides a procedure for the preparation of a salt of general formula I provided above, in which R 4 represents hydrogen,

according to which at least one compound of formula general R 1 -C (= O) -H (formula general II), in which R1 has the meaning given above, it is reacted with at least one compound of general formula III,

26

in which R3 and X have the meaning given above and R 'represents a radical linear or branched C 1-6 alkyl, a cation potassium or a sodium cation, in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base, to give at least one compound of general formula IV,

27

in which R 1, X and R 3 they have the meaning given above, which optionally it is purified and / or it isolates,

and at least one compound of general formula IV is reacts with at least one compound of general formula V,

28

or a corresponding salt of the themselves, in which R2 has the meaning given above, in a reaction medium, optionally in a inert atmosphere, optionally in the presence of at least one acid, to give at least one compound of general formula SAW,

29

in which R1, X, R2 and R3 have the meaning given above, which optionally it is isolated and / or purify,

and at least one compound of general formula VI is reacts with an activating agent in a reaction medium, optionally in an inert atmosphere, to give at least one compound of general formula VII,

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

30

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

in which R1, X, R2 and R3 have the meaning given above and LG represents a leaving group, which is optionally purified and / or isolates,

and at least one compound of general formula VII it is reacted with at least one compound of general formula NH 2 -NR 5 R 6, in which R 5 and R 6 have the meaning given above, in a medium reaction, optionally in an inert atmosphere, optionally in the presence of at least one base selected from the group that consists of diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine and N-methylmorpholine, to give the minus a compound of general formula VIII,

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

31

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

in which R 1, R 2, R 3, X, R 5 and R 6 have the meaning given above, which is optionally purified and / or isolates

or at least one compound of general formula VI is reacts with at least one compound of general formula NH 2 -NR 5 R 6, in which R 5 and R 6 have the meaning given above, in a medium reaction, in the presence of at least one coupling agent, optionally in the presence of at least one base, to give at least a compound of general formula VIII, which is optionally purified and / or it is isolated;

and at least one compound of general formula VIII it is reacted with at least one compound of general formula A-B, in which A and B have the meaning provided above, in a reaction medium, to give at least  a salt of general formula I,

32

wherein A, B, R1, R2, R 3, X, R 5 and R 6 have the meaning given above and R 4 represents hydrogen, which is optionally purify and / or be insulate

       \ vskip1.000000 \ baselineskip
    

The process of the invention is also illustrated in scheme I provided below:

Scheme I

33

In step 1 a compound of general formula II it is reacted with a compound of general formula III in a protic reaction medium, preferably in a reaction medium selected from the group consisting of methanol, ethanol, isopropanol, n-butanol, water and mixtures of themselves, in the presence of at least one base, preferably in presence of an alkali metal hydroxide such as hydroxide of sodium or potassium hydroxide or an alkali metal methoxide such as sodium methoxide, as described, for example, in Synthetic Communications, 26 (11), 2229-33, (nineteen ninety six). The respective description is incorporated as a reference to present document and form part of the description. Temperature of reaction, as well as the duration of the reaction, may vary in A wide interval. Preferred reaction temperatures range from -10 ° C to the boiling point of the reaction medium. The suitable reaction times may vary, for example, from several minutes to several hours.

Preferably the reaction between a compound of general formula II and a compound of general formula III it can also be carried out under acid catalyzed conditions, more preferably refluxing the aforementioned compounds previously in dichloromethane in the presence of copper (II) trifluoromethanesulfonate as described, for example, in Synlett, (1), 147-149, 2001. The respective description is incorporated by reference to this document and part of the description.

In step 2 a compound of general formula IV it is reacted with a compound of general formula V in a reaction medium, preferably in a reaction medium selected from the group consisting of methanol, ethanol, isopropanol, n-butanol, diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran or mixtures of at least two of the reaction media mentioned previously. Also preferably, said reaction may carried out in the presence of an acid, in which the acid can be organic such as acetic and / or inorganic acid such as acid hydrochloric. Alternatively the reaction can also be carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide or mixtures of at least two of these bases.

The reaction temperature as well as the duration of the reaction, it can vary over a wide range. The suitable reaction temperatures range from temperature ambient, that is, approximately 25 ° C, to the point of boiling of the reaction medium. Adequate reaction times they can vary, for example, from several minutes to several hours.

The carboxylic group of the compound of formula general VI can be activated for subsequent reactions by introduction of a suitable leaving group according to methods Conventionals well known to those skilled in the art. Preferably the compounds of general formula IV are transferred to an acid chloride, an acid anhydride, a mixed anhydride, a C 1-4 alkyl ester or an activated ester such as a p-nitrophenyl ester. Therefore a suitable activating agent is selected from the group consisting of thionyl chloride, oxalyl chloride and chloroformoate ethyl.

If said activated compound of general formula VII is an acid chloride, in which LG represents an atom of chlorine, that compound is preferably prepared by reaction of the corresponding acid of general formula VI with thionyl chloride or oxalyl chloride, wherein said Chlorination is also used as the reaction medium, in presence of at least one base, preferably in the presence of a base selected from the group consisting of triethylamine, N-methylmorpholine, pyridine, dimethylaminopyridine and diisopropylethylamine. It is also possible to preferably use a additional reaction medium. Suitable reaction media include hydrocarbons such as benzene, toluene or xylene, hydrocarbons halogenates such as dichloromethane, chloroform or tetrachloride carbon, ethers such as diethyl ether, dioxane, tetrahydrofuran or dimethoxyethane or dimethylformamide and mixtures thereof. Plus preferably toluene is used in the presence of an amount dimethylformamide catalyst as reaction medium. The Preferred reaction temperature ranges from 0 ° C to the point Boiling solvent and reaction times vary from several minutes to several hours.

If said activated compound of general formula VII is a mixed anhydride, in which LG represents -O-C (= O) -O-C 2 H 5, said anhydride can preferably be prepared, for example, by reacting the corresponding acid of the general formula VI with ethyl chloroformoate in the presence of a base such as triethylamine, pyridine or diisopropylethylamine, in a solvent suitable such as dichloromethane, optionally in an atmosphere inert, at a temperature between -50 ° C and 50 ° C.

In step 4 the reaction between a compound of general formula VII with a compound of general formula H-R3 to give a compound of general formula VIII is preferably carried out in the presence of such a base as triethylamine in a reaction medium such as methylene The temperature is preferably in the range of from 0 ° C to the boiling point of the reaction medium. He reaction time may vary over a wide range, by example, from several hours to several days.

In step 5, a compound of the general formula VI is reacted with a compound of general formula NH 2 -NR 5 R 6 in a reaction medium, preferably in a reaction medium selected from the group that It consists of diethyl ether, tetrahydrofuran, acetonitrile, methanol, ethanol, (1,2) -dichloroethane, dimethylformamide, dichloromethane and mixtures thereof, in the presence of at least one coupling agent, preferably in the presence of an agent coupling selected from the group consisting of hexafluorophosphate l-benzotriazolyloxy-tris- (dimethylamino) -phosphonium (BOP), dicyclohexylcarbodiimide (DCC), N '- (3-dimethylaminopropyl) -N-ethylcarbodiimide  (EDCI), diisopropylcarbodiimide, 1,1'-carbonyl diimidazole (CDI), N-oxide hexafluorophosphate N - [(dimethylamino) -1H-1,2,3-triazole [4, 5-b] pyridino-1-ylmethylene] -N-methylmethanamine (HATU), hexafluorophosphate O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium (HBTU), tetrafluoroborate O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium (TBTU), 1-hydroxy-benzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt), optionally in the presence of a base, preferably in presence of a base selected from the group consisting of pyridine, dimethylaminopyridine, N-methylmorpholine, triethylamine and diisopropylethylamine to give a compound of general formula I.

Preferably said reaction is carried out. in the presence of EDCI and HOBt, optionally in the presence of N-methylmorpholine or triethylamine, in a medium of aprotic reaction such as dimethylformamide or tetrahydrofuran, to a temperature between 20 ° C and 30 ° C for 15 to 24 hours such as described in Tetrahedron Lett. 2004, 45, 4977. The respective description is incorporated by reference to this document and part of the description. Can also be used suitably EDCI supported on polymer (P-EDCI) for this procedure instead of EDCI as described in Tetrahedron Lett. 1998, 39, 1487 and Tetrahedron Lett. 2002, 43, 7685. The respective descriptions are incorporated by reference to this document and are part of the description.

Alternatively said reaction can be carried to out using HBTU in the presence of a base such as diisopropylethylamine in an aprotic solvent, such as acetonitrile, preferably at a temperature between 20 and 30 ° C for 15 to 24 hours.

In step 6, a compound of the general formula VIII or a compound of general formula IX,

3. 4

in which R 1, R 2, R 3, R 4, R 5, R 6 and X have the meaning facilitated above, it is reacted with a compound of general formula A-B, in which A represents a unsubstituted or at least monosubstituted alkyl radical, preferably a C 1-10 alkyl radical not substituted and B represents an anion selected from the group that consists of fluoride, chloride, bromide and iodide, in a medium of reaction, preferably in a reaction medium selected from the group consisting of chloroform, acetone, acetonitrile, dichloromethane, carbon tetrachloride, toluene and mixtures of reaction media mentioned above, at a temperature between 0 ° C and 120 ° C, preferably at a temperature between 20 ° C and 100 ° C, to provide a salt of general formula I. The duration of the reaction may vary over a wide range. Times of Suitable reactions vary, for example, from several minutes to several hours.

Alternatively, a compound of formula general VIII or IX provided above is reacted with an acid of general formula A-B, in which A represents a hydrogen atom and B represents an anion selected from the group consisting of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or unsubstituted naphthoate or at least monosubstituted, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

35

in which R 12 and R 13 they have the meaning given above; in a middle of reaction, preferably in a reaction medium selected from the group consisting of ethyl acetate, chloroform, acetone, acetonitrile, dichloromethane, carbon tetrachloride, toluene, methanol, ethanol, 2-propanol, (1,4) -dioxane, tetrahydrofuran and mixtures of the reaction media mentioned above, at a temperature between 0 ° C and 50 ° C, preferably at a temperature between 5 ° C and 40 ° C, for less than one hour, preferably for less than 30 minutes, more preferably for less than 10 minutes, to provide a general formula salt I.

Suitable acids include hydrochloric acid, hydrofluoric, hydroiodic or hydrobromic; sulfuric acid, phosphoric, nitric or perchloric; thiocyanic acid; cyanic acid; acid cyclamic; aliphatic or aromatic carboxylic acids or sulfonic acids, for example, formic acid, acetic acid, propionic acid, succinic, glycolic, lactic, malic, tartaric, gluconic, citric, ascorbic, maleic, fumaric, pyruvic, phenylacetic, benzoic, 4-aminobenzoic, anthranilic, 4-hydroxybenzoic, salicylic, 4-aminosalicylic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethane-1,2-disulfonic acid, benzenesulfonic, p-toluenesulfonic, naphthalene-2-sulfonic, hydroquinonasulfonic, camphorsulfonic, naphthalene-1,5-disulfonic, n-dodecyl sulfonic, sulphanilic or cyclohexylsulfamic.

Suitable acids also include acid 3-amino-1-propanesulfonic acid, aniline-2-sulfonic acid, acid 3-pyridinsulfonic acid 4-amino-3-hydroxy-1-naphthalenesulfonic acid, acid 2-amino-1,5-naphthalenedisulfonic acid, aminomethanesulfonic acid, acid 2-mesitylenesulfonic acid 7-amino-1,3-naphthalenedisulfonic acid, (2,5) -diaminobenzenesulfonic acid, acid trifluoromethanesulfonic acid 1-naphthalenesulfonic acid 6-amino-m-toluenesulfonic acid, acid 2-phenylbenzimidazol-5-sulfonic acid, acid 1-amino-benzimidazol-2-sulfonic acid, acid 1H-benzimidazol-2-sulfonic acid, acid 1-methylbenzimidazol-2-sulfonic acid, 5-isoquinolinsulfonic acid, 3-amino-4-chlorobenzenesulfonic acid, 5-isoquinolinsulfonic acid 3-amino-4-methoxybenzenesulfonic acid, 5-isoquinolinsulfonic acid 2-amino-5-methoxybenzenesulfonic acid, 5-isoquinolinsulfonic acid 2,4-diaminobenzenesulfonic acid 5-isoquinolinsulfonic (3,5) -diamino-2,4,6-trimethylbenzenesulfonic acid, (2,5) -disulfoaniline, acid 2-aminopropyl sulfonic acid 4-amino-1-naphthalenesulfonic acid, acid 8-amino-1-naphthol-5-sulfonic acid, methanilic acid, acid 5-Chloro-1,3-dimethyl-1H-pyrazol-4-sulfonic acid, acid 8-chloronaphthalene-1-sulfonic acid, acid (2,5) -dihydroxybenzenesulfonic and acid 4-amino-3-nitrobenzene-1-sulfonic.

Hydrochloric acid is preferably used. as a methanolic, ethanolic, ethereal or aqueous solution. Alternatively, hydrogen chloride gas can also be used for the preparation of salts of general formula I provided above.

In the case that R 4 is different from hydrogen, the reaction sequence provided in scheme I is adapt as follows.

Scheme II

36

In step 1 a compound of general formula IIIb is reacted with a compound of general formula II in a reaction medium, preferably in a reaction medium protic, more preferably in a selected reaction medium from the group consisting of methanol, ethanol, isopropanol, n-butanol, water and mixtures thereof, in presence of at least one base, preferably in the presence of a alkali metal hydroxide such as sodium hydroxide or hydroxide of potassium or an alkali metal methoxide such as methoxide sodium, or in the presence of lithium diisopropylamide in a solvent aprotic, preferably in tetrahydrofuran.

In step 2, a compound of the general formula XI is transformed into a compound of general formula XII that contains a good leaving group LG, preferably a group outgoing selected from the group consisting of mesyl and tosyl, using conventional methods known to those skilled in the technique.

In step 3, a compound of the general formula XII is reacted with a compound of general formula V in a reaction medium, preferably in a reaction medium selected from the group consisting of methanol, ethanol, isopropanol, n-butanol, diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran or mixtures of at least two of these media reaction mentioned above. Therefore, preferably said reaction can be carried out in the presence of an acid, in which the acid can be an organic acid such as acetic acid and / or inorganic, such as hydrochloric acid. Alternatively, the reaction can also be carried out in the presence of such a base such as piperidine, piperazine, sodium hydroxide, hydroxide potassium, sodium methoxide or sodium ethoxide or mixtures of at least Two of these bases. The reaction temperature as well as the time reaction, may vary over a wide range. The temperatures Suitable reaction ranges from room temperature, it is say approximately 25 ° C to the boiling point of the medium of reaction. Suitable reaction times may vary, by example, from several minutes to several hours.

Stage 4 can be carried out as it is described for stage 3, scheme I; stage 5 can be taken to out as described for stage 5, scheme I, stage 6 can be carried out as described for step 4, scheme 1 and step 7 can be carried out as described for stage 6, scheme I.

The reactions mentioned above that assume the synthesis of the ring of 4,5-dihydro-pyrazole or the reaction of a compound comprising said ring are carried out preferably under an inert atmosphere, preferably under a nitrogen or argon atmosphere, to prevent oxidation of cyclic system

During some synthetic reactions described previously, the protection of reactive or sensitive groups. This can be done using conventional protective groups, such as those described in Protective groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M. Wuts and Protective Groups in Organic Chemistry, John Wiley & sons, 1991. The respective parts of The description is incorporated by reference to this document and are part of the description. Protective groups can be eliminated when convenient by means well known to experts in the art.

If the substituted pyrazoline compounds and / or quaternary ammonium salts of pyrazoline compounds substitutes of general formula I provided above are obtained in the form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures can be separated by usual procedures known to experts in the technique, for example, chromatographic methods or crystallization with chiral reagents It is also possible to obtain stereoisomers pure through stereoselective synthesis.

You can also get solvates, preferably hydrates, of quaternary ammonium salts of the substituted pyrazoline compounds, of the corresponding stereoisomers or the corresponding diastereomers of the same by usual procedures known to experts in the art.

The purification and isolation of substituted pyrazoline compounds and / or ammonium salts quaternary of the substituted pyrazoline compounds, of a corresponding stereoisomer, or diastereomer or solvate or any intermediate product thereof can be carried out, if desired, by conventional methods known to skilled in the art, for example, chromatographic methods or recrystallization

The quaternary ammonium salts of substituted pyrazoline compounds of general formula I provided above can also act as prodrugs, that is, they represent a drug precursor, which upon administration to a patient releases the drug in vivo through some kind of process. chemical and / or physiological (for example, when a prodrug is taken at physiological pH and / or through the action of an enzyme it becomes a desired pharmacological form; see, for example, RB Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action ", Academic Press, Chapter 8). In particular, the compounds of general formula I give rise to a compound of general formula XIII,

37

       \ vskip1.000000 \ baselineskip
    

in which R 1, R 2, R 3, R 4 and X have the meaning given previously, after administration to a patient.

Prodrugs can be used to alter biodistribution (for example, to allow compounds that normally they would not enter the reactive site of the protease) or the Pharmacokinetics of a specific compound. For example, you can esterify a hydroxyl group, for example with an acid group carboxylic to give an ester. When the ester is administered to a subject, the ester is cleaved, enzymatically or not enzymatically, reductively or hydrolytically, to leave discovered the hydroxyl group.

Quaternary ammonium salts of compounds of  substituted pyrazoline of general formula I provided previously, its stereoisomers, its diastereomers and corresponding solvates are toxicologically acceptable and, for both suitable and active pharmaceutical ingredients for the medication preparation

It has been found that ammonium salts quaternary of substituted pyrazoline compounds of formula general I provided above, stereoisomers thereof, diastereomers thereof and corresponding solvates have a high affinity for cannabinoid receptors, particularly cannabinoid 1 (CB1) receptors, that is, are selective ligands for the CB1 receptor and act as modulators, for example antagonists, inverse agonists or agonists, in these receptors. In particular, these salts of quaternary ammonium of substituted pyrazoline compounds of general formula I provided above show little or no development of tolerance during treatment, particularly with respect to food intake, that is, if the treatment is interrupted for a period of time and then it continues later, the pyrazoline compounds used according to the invention they will show again the desired effect. After finish treatment with pyrazoline compounds, it find that the positive influence on weight continues bodily.

In addition, these quaternary ammonium salts of substituted pyrazoline compounds show an affinity for relatively weak Herg channel, therefore, for these compounds expects a low risk of prolongation of the QT interval.

In summary, quaternary ammonium salts of substituted pyrazoline compounds of formula I provided previously distinguished by a wide spectrum of effects beneficial while at the same time show relatively few unwanted effects, that is, effects that do not contribute positive way to or that even interfere with the welfare of patient.

Therefore, another aspect of the present invention refers to a medicament comprising at least ammonium salts quaternary of the substituted pyrazoline compounds of formula general I provided above, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof, and optionally at least one agent Physiologically acceptable auxiliary.

Preferably said medicament is suitable. for the modulation (regulation) of cannabinoid receptors, preferably of the cannabinoid 1 (CB1) receptors, for the prophylaxis and / or treatment of system disorders central nervous, immune system disorders, disorders of the cardiovascular system, disorders of the endocrine system, respiratory system disorders, tract disorders gastrointestinal or reproductive disorders.

Particularly, preferably said medication is suitable for prophylaxis and / or treatment of  psychosis.

In addition, particularly preferably said medication is suitable for prophylaxis and / or the treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity and / or diabetes Type II mellitus (non-insulin dependent diabetes mellitus), plus preferably of obesity. The medicament of the invention It also appears to be active in the prophylaxis and / or treatment of appetite disorders, for example, ammonium salts quaternary of the substituted pyrazoline compounds also They reduce the desire to eat sweets.

The use of al is also particularly preferred.  minus one of the pyrazoline compounds as defined in this document and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the treatment of metabolic syndrome.

The metabolic syndrome and its definitions are described in detail by Eckel et al ., The Lancet, Vol. 365 (2005), 1415-1428, included as a reference herein. One of the respective definitions was established by WHO in 1998 (as described in Alberti et al ., Diabet. Med. 1998, 15, pages 539-53, the respective description of the same is incorporated by reference to this document and form part of this description). The other, more widespread definition of metabolic syndrome was established by the Adult Treatment Panel (ATP III) of the US National Cholesterol Education Program (NCEP) in 2001 , as described in JAMA 2001; 285; 2486-97, the respective description thereof is incorporated by reference to this document and forms part of this description.

The metabolic syndrome is characterized by a interaction of several physiological parameters such as triglycerides, lipids, blood pressure, blood sugar levels and insulin.

Even when obesity can play a role  critical in the development of metabolic syndrome, many of its aspects are independent of weight, especially some lipid parameters. Especially, the positive influence on the independent aspects of the weight of the metabolic syndrome (see, for example, Pagotto and Pasquali, The Lancet, Vol. 365 (2005), 1363, 1364, included as a reference herein document) like some blood parameters, especially Lipid parameters, is one of the main and surprising Advantages of the substituted pyrazoline compounds used according to the invention.

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a medicine for the improvement of cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

       \ vskip1.000000 \ baselineskip
    

Elevated triglycerides, in which levels elevated triglycerides are preferably understood to be> 150 mg / dl,

Low HDL cholesterol, in which the low cholesterol levels of HDL is preferably understood which are <40 mg / dl in men and <50 mg / dl in women,

Hypertension, in which hypertension is understood  preferably that is> 130/85 mmHg,

Fasting impaired glucose, in which the  fasting impaired glycemia is preferably understood which is> 110 mg / dl,

Insulin resistance

Dyslipidemia

       \ vskip1.000000 \ baselineskip
    

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a medicine for the treatment of the independent aspects of the weight of the syndrome metabolic.

Another aspect of the invention is a method for improve cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

       \ vskip1.000000 \ baselineskip
    

Elevated triglycerides, in which levels elevated triglycerides are preferably understood to be> 150 mg / dl,

Low HDL cholesterol, in which the low cholesterol levels of HDL is preferably understood which are <40 mg / dl in men and <50 mg / dl in women,

Hypertension, in which hypertension is understood  preferably that is> 130/85 mmHg,

Fasting impaired glucose, in which the  fasting impaired glycemia is preferably understood which is> 110 mg / dl,

Insulin resistance

Dyslipidemia,

in a subject, preferably a human being.

       \ vskip1.000000 \ baselineskip
    

Another aspect of the invention is a method for treat independent aspects of the weight of the syndrome metabolic.

In addition, particularly preferably said medication is suitable for prophylaxis and / or the cancer treatment, preferably for prophylaxis and / or the treatment of one or more types of cancers selected from the group which consists of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, cancer liver, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of cancer of colon, bowel cancer and prostate cancer.

Particularly preferably said medication is suitable for prophylaxis and / or treatment of alcoholism and / or alcohol addiction, nicotine abuse and / or smoking, drug abuse and / or drug addiction and / or drug abuse and / or drug dependence, preferably drug abuse and / or drug addiction and / or abuse of nicotine and / or smoking.

       \ newpage
    

Therefore, the medicament of the invention is active in the treatment of withdrawal, desire reduction and the prevention of recidivism in alcohol intake. He medicament of the invention can also be used in the prophylaxis and / or treatment of addiction, suppression and / or tobacco dependence, which includes treatment for reduction of desire and prevention of recidivism from smoking tobacco.

Medications and / or drugs that are frequently subject to abuse include opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and Benzodiazepines

The medicine is also suitable for prophylaxis and / or treatment of one or more of the disorders selected from the group consisting of bone disorders, preferably osteoporosis (for example, associated osteoporosis with a genetic predisposition, sex hormone deficit or aging), bone disease associated with cancer or disease Paget's bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, disorders spinocerebellar, cognitive disorders, head trauma, head trauma, stroke, seizures panic, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremors, disorders compulsive, senile dementia, thymic disorders, tardive dyskinesia,  bipolar disorders, movement disorders induced by medications, dystonia, endotoxémic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclera, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic pain relievers, or to influence the intestinal transit.

The medicine is also suitable for prophylaxis and / or treatment of one or more of the disorders selected from the group consisting of dementia and disorders related, preferably for the prophylaxis and / or treatment of one or more types of dementia selected from the group consisting of memory loss, vascular dementia, mild cognitive impairment, Frontotemporal dementia and Pick's disease; disorders by binge binge; youth obesity; obesity induced by drugs; metabolic syndrome; atypical depression; addictions of behavior; attention deficit disorders; syndrome of Tourette; suppression of behaviors related to reward; for example, avoid conditioning by a place, such as the suppression of preference conditioned by a place induced by cocaine and morphine; impulsiveness; dysfunction sexual; preferably, for the prophylaxis and / or treatment of one or more types of sexual dysfunction selected from the group that it consists of erectile difficulty and female sexual dysfunction; seizure disorders; sickness; emesis; disease neuroinflammatory, preferably for prophylaxis and / or treatment of one or more types of neuroinflammatory diseases selected from the group consisting of multiple sclerosis, disorders related to demyelination syndrome Guillan-Barré, viral encephalitis and accidents cerebrovascular; Neurological disorders; muscle spasticity; traumatic brain injury; spinal cord injury; inflammation disorders and immunomodulators, preferably for the treatment and / or prophylaxis of one or more types of inflammation disorders and immunomodulators selected from group consisting of cutaneous T-cell lymphomas, arthritis rheumatoid, systemic lupus erythematosus, sepsis, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, disease retinal, scleroderma, renal ischemia, myocardial infarction, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, Cryptogenic fibrosing alveolitis, psoriasis, rejection of transplants, atopic dermatitis, vasculitis, allergy, rhinitis seasonal allergic, Crohn's disease, inflammatory disease of the intestine, reversible airway obstruction, adult respiratory failure syndrome, lung disease chronic obstructive and bronchitis; cerebral apoplexy; trauma craniocerebral; neuropathic damage disorders; gastric ulcers; atherosclerosis, and liver cirrhosis.

Another aspect of the present invention is the use of at least one quaternary ammonium salt of general formula I previously provided as active ingredients, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof, and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the modulation of cannabinoid receptors, preferably cannabinoid 1 receptors (CB1), for prophylaxis and / or treatment of nervous system disorders central, immune system disorders, system disorders cardiovascular, endocrine system disorders, disorders of the respiratory system, gastrointestinal tract disorders or reproductive disorders

Particularly preferred is the use of at least one of the respective quaternary ammonium salts of the formula general I provided above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a  medication for prophylaxis and / or treatment of psychosis.

The use of al is also particularly preferred.  minus one of the respective quaternary ammonium salts of general formula I provided above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof, and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the prophylaxis and / or treatment of ingestion disorders of food, preferably bulimia, anorexia, cachexia, obesity and / or type II diabetes mellitus (diabetes mellitus no insulin dependent), more preferably obesity.

The use of al is also particularly preferred.  minus one of the respective quaternary ammonium salts of general formula I provided above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a solvate corresponding thereof, and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, cancer pancreas, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for prophylaxis and / or  treatment of one or more types of cancers selected from the group consisting of colon cancer, intestinal cancer and cancer of prostate.

The use of al is also particularly preferred.  minus a quaternary ammonium salt of pyrazoline compounds substitutes of general formula I provided above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason mixing, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the treatment of alcoholism and / or alcohol addiction, abuse of nicotine and / or smoking, drug abuse and / or drug addiction and / or abuse of drugs and / or drug dependence, preferably drug abuse and / or drug addiction and / or abuse of nicotine and / or smoking.

Medications / drugs, which are frequently subject to abuse include opioids, barbiturates, cannabis, cocaine,  amphetamines, phencyclidine, hallucinogens and benzodiazepines.

The use of at least one of the respective quaternary ammonium salts of compounds of substituted pyrazoline of general formula I provided above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the themselves, and optionally one or more pharmaceutically excipients acceptable, for the preparation of a medicine for prophylaxis and / or treatment of one or more selected disorders from the group consisting of bone disorders, preferably osteoporosis (for example, osteoporosis associated with a genetic predisposition, sex hormone deficit or aging), bone disease associated with cancer or bone disease from Paget; schizophrenia, anxiety, depression, epilepsy, disorders neurodegenerative, cerebellar disorders, disorders spinocerebellar, cognitive disorders, head trauma, head trauma, stroke, seizures panic, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremors, disorders compulsive, senile dementia, thymic disorders, tardive dyskinesia,  bipolar disorders, movement disorders induced by medications, dystonia, endotoxémic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclera, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic pain relievers, or to influence the intestinal transit.

Also preferred is the use of at least one of the respective quaternary ammonium salts of substituted pyrazoline compounds of general formula I provided above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for prophylaxis and / or the treatment of one or more disorders selected from the group consisting of dementia and related disorders, preferably for the prophylaxis and / or treatment of one or more types of dementia selected from the group consisting of memory loss, vascular dementia, cognitive impairment mild ivo, frontotemporal dementia and Pick's disease; binge eating disorders; youth obesity; drug induced obesity; metabolic syndrome; atypical depression; behavioral addictions; attention deficit disorders; Tourette syndrome; suppression of behaviors related to the reward; for example, avoid conditioning by a place, such as the suppression of preference conditioned by a place induced by cocaine and morphine; impulsiveness; sexual dysfunction; preferably, for the prophylaxis and / or treatment of one or more types of sexual dysfunction selected from the group consisting of erectile difficulty and female sexual dysfunction; seizure disorders; sickness; emesis; neuroinflammatory disease, preferably for the prophylaxis and / or treatment of one or more types of neuroinflammatory diseases selected from the group consisting of multiple sclerosis, disorders related to demyelination, Guillan-Barré syndrome, viral encephalitis and strokes; Neurological disorders; muscle spasticity; traumatic brain injury; spinal cord injury; inflammation and immunomodulatory disorders, preferably for the treatment and / or prophylaxis of one or more types of inflammation and immunomodulatory disorders selected from the group consisting of cutaneous T-cell lymphomas, rheumatoid arthritis, systemic lupus erythematosus, sepsis, sarcoidosis, Idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, renal ischemia, myocardial infarction, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing alveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory failure syndrome, chronic obstructive pulmonary disease and bronchitis; cerebral apoplexy;
craniocerebral trauma; neuropathic damage disorders; gastric ulcers; atherosclerosis, and liver cirrhosis.

Dementia is a disease characterized by the progressive deterioration of cognitive functions and of social adaptation that can ultimately interfere with capacity of the patient to live independently. Dementia too it is constituted by a short and long memory deficiency term plus additional symptoms, such as problems with the Abstract thinking, opinion and personality. It is estimated that in the world there are 18 million patients suffering from dementia. The most common forms of dementia include the disease of Alzheimer's and vascular dementia. Other forms are dementia Frontotemporal and Pick's disease.

Dementia can also be of origin vascular. Vascular dementia (cerebrovascular disease atherosclerotic) is considered to be the second most common dementia in old age, affecting approximately one 10-15% of all cases. AD and dementia vascular may exist isolated or together (mixed dementia). In the vascular dementia, atherosclerotic changes in the vessels brain can lead to less local blood flow that gives place to multiple small infarcts (multi-infarct dementia). The Vascular dementia is treated pharmacologically by prophylaxis of heart attack and by treating cognitive deficit.

Alzheimer's disease (AD), the most common and important dementia, is a degenerative disorder that  characterized by progressive deterioration of functions Cognitive, such as abstract reasoning and memory. Currently, it is estimated that there are 2 million people in States United and 12 million worldwide that are affected by this disease. Due to the increase in life expectancy, it is expected that in the year 2050 there will be around 100 million patients worldwide with AD. AD is one of the most widespread diseases in the old age. Most patients with AD are in their 60s or plus. More than 5% of all people over 70 have a significant memory loss due to AD.

AD is mainly characterized by a Gradual development of the ability to forget. In the phases more advanced disease, the increase in others is observed failures in brain function. This includes speech impairment, writing and arithmetic skills. The orientation visiospace, such as parking a car, dressing correctly and give and understand directions for a location They may be defective or damaged. In the last stage of the disease, patients forget how to use objects and common tools while maintaining motive energy and necessary coordination for these activities.

Schizophrenia is characterized by a profound alteration in cognition and emotion affecting the most fundamental human attributes: language, thought, perception, affection and sense of self. Positive symptoms include psychotic manifestations, such as voice listening internal or experimentation of other feelings not connected with an obvious origin (hallucinations) and the assignment of a importance or unusual meaning to normal events or the maintenance of false personal beliefs (illusions). The Negative symptoms are characterized by affective flattening and a lack of initiative or objectives (lack of motivation), loss of usual interests or pleasures (anhedonia), sleep and eating disturbances, dysphoric humor (humor depressive, anxious, irritable or angry) and difficulty focus or focus attention.

Major depression is a disorder with multiple  facets characterized mainly by dysphoric humor and loss of interest or pleasure in activities that were once enjoyable Other physical and psychological symptoms include inability to concentrate, motor disturbances (delay or psychomotor agitation), feelings of worthlessness, guilt inappropriate, thoughts of suicide, and disturbances in the appetite and sleep

Anxiety disorders are a group of syndromes that include a generalized anxiety disorder, panic disorder, phobias, disorder compulsive-obsessive and post stress disorders traumatic. Although each disorder has its own characteristics distinctive, all share common symptoms of concern excessive, intense fears and fears, hypervigilance and / or symptoms somatic, in the absence of a dangerous situation.

Normal sexual function requires, among others things, the ability to get and maintain an erection of the penis. The main anatomical structures of the penis that are involved in erectile function include the corpora cavernosa, the prickly body and tunica albuginea (a collagen sheath that surround each body). The bodies are composed of a mass of smooth muscle (trabecula) that contains a network of coated vessels by endothelial tissue (lacunar spaces). The tumenescence of penis and erection are caused by the relaxation of the arteries and smooth body muscles, while the veins close emissary, leading to increased blood flow in the network lacunar. Central and peripheral innervation contributes to the regulation of the erectile response.

Erectile dysfunction (ED) can result from a  insufficient to initiate, fill or store the volume of adequate blood in the lacunar network of the penis. Depending on the underlying dysfunction, ED can be vasculogenic, neurogenic, endocrinological, diabetic, psychogenic or related to medication.

ED affects 10-25% of middle-aged and elderly men and has a profound impact on The welfare of the affected men. It is currently using PDE5 inhibitors, such as vardenafil, tadalfil and sildenafil Intraurethral alpostadil can be used (prostaglandin EI) in patients who do not work oral agents In addition, vacuum constriction devices (VCC) are a well established non-invasive therapy.

Female sexual dysfunction (FSD) is highly extended, it is related to age and is progressive. It affects 30 to 50 or women. The FSD represents a range of medical problems and is classified according to the disorders of (1) desire, (2) arousal, (3) orgasm and (4) sexual damage, and symptoms that include decreased vaginal lubrication, pain and discomfort in intercourse, decreased arousal, and difficulty To get orgasm. At the molecular level, it has been suggested that vasoactive intestinal peptide (VIP), nitric oxide (NO) and sex hormones, such as estrogens and androgens, are important in female sexual function. The approaches of Current treatments include replacement therapy estrogen, methyl testosterone, PDE5 inhibitors, such as sildenafil, NO-giving L-arginine, prostaglandin EI, phentolamine and dopamine agonists such as apomorphine.

The medicament according to the present invention can be in any form suitable for application to beings humans and / or animals, preferably humans including infants, children and adults and can be produced by usual procedures known to those skilled in the art. The medicine can be produced by usual procedures known to those skilled in the art, for example, from "Pharmaceutics: The Science of Dosage Forms" index, second edition, Aulton, M.E. (ED. Churchill Livingstone, Edinburgh  (2002); "Encyclopedia of Pharmaceutical Technology", second edition, Swarbrick, J. and Boylan J.C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics", fourth edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York 2002 and "The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective descriptions are incorporated as reference to this document and are part of the description. The composition of the medication may vary depending on the route of administration.

The medicament of the present invention can administered, for example, parenterally in combination with conventional injectable liquid vehicles, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizing agents, agents solubilizers and buffers, can be included in such compositions injectable These medications can be injected, for example, by intramuscularly, intraperitoneally or via intravenous

Medications according to the present invention they can also be formulated in compositions that can be administered orally, containing one or more vehicles or excipients physiologically compatible, in solid or liquid form. These compositions may contain conventional components, such as binding agents, fillers, lubricants and agents acceptable humectants. The compositions can take any Convenient form, such as tablets, microgranules, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powder forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or sustained release. The forms multiparticulates, such as pellets or granules, can be filled, for example, a capsule, compressed for tablets or Suspend in a suitable liquid.

The prior art knows the adequate sustained release formulations, materials and methods for its preparation, for example the indices of "Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology ", Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000); "Controlled Drug Delivery", Vol, I, Basic Concepts, Bruck, S.D. (Ed.), CRD Press Inc., Boca Raton (1983) and of Takada, K. and Yoshikawa, H., "Oral Drug Delivery", Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon", Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 698-728. The respective descriptions are incorporate as reference to this document and are part of the description.

Medications according to the present invention they can also comprise an enteric coating, so that Its dissolution depends on the pH value. Because of said coating, the medicine can pass through the stomach without dissolve and the respective phenylpiperazine compound Nitrosubstituted is released in the intestinal tract. Preferably, The enteric coating is soluble at pH values of 5 to 7.5. From prior art materials and methods suitable for the preparation.

Normally, medications according to this invention may contain 1-60% by weight of one or more of the quaternary ammonium salts of pyrazoline compounds substituted as defined herein and of the 40-99% by weight of one or more auxiliary substances (additives).

Liquid oral forms for administration they can also contain various additives such as agents sweeteners, flavorings, preservatives and emulsifiers. Too non-aqueous liquid compositions can be formulated for Oral administration containing edible oils. Such liquid compositions can be conveniently encapsulated in, by example, gelatin capsules in a dose amount unitary.

The compositions of the present invention they can also be administered topically or through a suppository.

The daily dosage for humans and Animals may vary depending on factors that are based on  the respective species or other factors, such as age, sex, weight or degree of illness, etc. Dosage daily for humans can preferably be in the range from 1 to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active ingredient that is going to administered during one or several intakes per day.

Pharmacological methods I. In vitro determination of affinity for CB1 / CB2 receptors

a) In-vitro determination of the affinity of the quaternary ammonium salts of the invention for the CB1 / CB2 receptors is carried out as described in the publication of Ruth A. Ross, Heather C Brockie et al ., "Agonist-inverse agonist characterization at CB_ {1} and CB_ {cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999), in The transfected human CB1 and CB2 receptors of Receptor Biology, Inc. are used. The radioligand used for both receptors is [3 H] -CP55940. The respective parts are incorporated by reference to this document and are part of this description.

b) Binding to CB1 of mouse cerebellum

CB1 receptor binding affinity was evaluated according to a modification of the method described by Govaerts et al ., Eur. J. Pharmac. Sci. 23, 233-243 (2004). The respective parts of the description are incorporated by reference herein and form part of the present description.

Briefly, they were dissected carefully cereals of male wistar rats (250-300 g) on ice and homogenates were prepared with Potter-Helveheim in a cold solution of 50 mM Tris-HCl containing 5 mM MgCl2, 1 mM EDTA and 0.25 M sucrose, pH 7.4. The suspension is centrifuged at 1,000 x g for 5 minutes. The ones were collected supernatants and centrifuged at 50,000 x g for 15 minutes. The resulting pellets were then resuspended in buffer Tris-HCl without sucrose, homogenized and incubated for 15 minutes at 37 ° C in an orbital shaking bath and centrifuged again at 50,000 x g for 15 minutes. The pellets were weighed, resuspended in the buffer Tris-HCl without sucrose, were homogenized with Ultraturrax at 13,500 rpm for 3 x 5 seconds and they were put in aliquots in volumes of 0.9 ml in Eppendorf tubes. Aliquots were centrifuged at 20,800 x g for 5 minutes, discarded supernatants and the pellets were frozen at -80 ° C until utilization. Total protein concentration was determined. using a kit based on the Bio-Rad method Lowry

Competitive binding experiments were performed in the presence of [3 H] -CP 55,940 1 nM in tubes silicon glass containing 100 µg protein / tube resuspended in a final volume of 1 ml of 50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.5% (w / v) bovine serum albumin, pH 7.4. The compounds were present in various concentrations and binding was determined non-specific in the presence of 10 µM of HU-210. After 1 hour incubation at 30 ° C, the suspension was filtered quickly through pre-treated GF / B fiber filters with 0.5% PEI in a 96-well collection plate and washed 3 times with 3 ml of ice-cold binding buffer without bovine serum albumin. Radioactivity in the filters was measured with a Wallac Winspectral 1414 counter by liquid scintillation in 6 ml of Ecoscint H (Natinal Diagnostics, UK). Rehearsals are They performed in triplicate.

Binding data were analyzed by Nonlinear regression with GraphPad Prism Version software 3.03.

II. In vivo bioassay system to determine cannabinoid activity Mouse tetrad model

It is known that substances with affinity for cannabinoid receptors produce a wide range of effects Pharmacological It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice it produces analgesia, hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has an affinity for cannabinoid receptors, since all these effects are common for various kinds of active agents in the nervous system central. However, the substances that show all these effects, that is, the substances that are active in this model called tetrad, they are considered to have affinity for cannabinoid receptors It has also been shown that cannabinoid receptor antagonists are extremely effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.

The tetrad model is described, for example, in the publication of AC Howlett et al , International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202, 2002 and David R. Compton et al ., " In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol. Exp. Ther. 277, 2, 586-594, 1996. The corresponding parts of the description are incorporated by reference to this document.

Material and methods

In all the following experiments they are used  NMRI male mice weighing 20-30 g (Harlan, Barcelona, Spain).

Before the tests in the procedures behavioral behaviors then the mice acclimatize to the experimental environment. Control values prior to treatment were determined to measure analgesia using hot plate latency (in seconds), rectal temperature, sedation and catalepsy.

In order to determine agonist activity of the substance to be tested, mice are injected by intravenously the substance to be tested or the vehicle alone. 15 minutes after the injection, the latency of hot plate analgesia. 20 minutes after the injection It measures rectal temperature, sedation and catalepsy.

In order to determine the activity antagonist, the identical procedure is used as for determination of agonist effects, but with the difference of that the substance to be evaluated to determine its activity antagonist is injected 5 minutes before intravenous injection of 1.25 mg / kg of Win-55,212, a known agonist of the cannabinoid receptor.

Hot plate analgesia

Hot plate analgesia is determined according to the method described in Woolfe D. et al . "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307, 1944. The respective description is incorporated as a reference to this document and is part of this description.

The mice are placed on a hot plate (Harvard analgesimeter) at 55 ± 0.5 ° C until they show a painful sensation, licking its legs or jumping, and registers the time for these sensations to occur. This reading is consider as the baseline value (B). The maximum time limit that mice are allowed to remain on the hot plate in absence of any painful response is 40 seconds with the In order to avoid skin lesions. This period is called time. limit (PC).

Fifteen minutes after the administration of the substance to be tested, the mice are placed again on the hot plate and the procedure is repeated above described This period is called post-treatment reading. (PT).

The degree of analgesia is calculated from the formula:

% MPE of analgesia = (PT- B) / (PC-B) x 100

MPE = maximum possible effect.

Determination of sedation and ataxia

Sedation and ataxia are determined according to the method described in Desmet LKC et al . "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975. The respective description is incorporated by reference to this document and forms part of this description.

The scoring system chosen is

       \ vskip1.000000 \ baselineskip
    

0: no ataxia;

1: doubtful;

2: obvious tranquility and silence;

3: pronounced ataxia;

before, in addition to after treatment.

       \ vskip1.000000 \ baselineskip
    

The percentage of sedation is determined according to the formula:

Sedation% = arithmetic mean / 3 X 100

Hypothermia

Hypothermia is determined according to the method described in David R. Compton et al . " In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A) Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther. 277, 2, 586-594, 1996. The respective description is incorporated by reference to this document and forms part of this description.

Rectal temperatures are determined initials with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted 25 mm before the administration of the substance to be tested. Temperature rectal is measured again 20 minutes after administration of the substances to be tested. The temperature difference is calculate for each animal, so that the differences ≥ -2 ° C They are considered to represent activity.

Catalepsy

Catalepsy is determined according to the method described in Alpermann HG et al . "Pharmacological effets of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is incorporated by reference to this document and forms part of this description.

The cataleptic effect of the substance that is going to be tested is evaluated according to the duration of the catalepsy, putting the animals head down with their legs on top of the wood block.

The scoring system chosen is:

Catalepsy during:

more than 60 seconds = 6; 50 -60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds = 0.

The percentage of catalepsy is determined according to the following formula:

% of catalepsy = arithmetic mean / 6 X 100

III. In vivo tests to determine activity against obesity a) Acute treatment

Normally treated rats were habituated at a 12/12 h reverse cycle, and the candidate compound, as well as the saline solution, were orally administered acutely. After administration, cumulative food intake (g) was measured at 6 h and 24 h. After this, the difference in body weight between the control animals and the animals treated with the compound was measured. This is a variation of the test according to Colombo et al . as described below.

b) Long-term treatment

In vivo tests to determine the activity against obesity of the pyrazoline compounds of the invention are carried out as described in the publication of G. Colombo et al ., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716 "; Life Sciences, 63 (8), 113-117, (1998). The respective part of the description is incorporated as a reference to this document and is part of this description.

IV. In vivo tests to determine antidepressant activity

In vivo tests to determine the antidepressant activity of the pyrazoline compounds of the invention in the forced swimming test are carried out as described in the publication of ET Tzavara et al ., "The CB1 receptor antagonist SR141716A selectively increases monoaminargic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions "; Br. J. Pharmacol. 2003, 138 (4): 544: 53. The respective part of the description is incorporated as a reference to this document and is part of this description.

V. In vitro determination of antagonism for the CB1 receptor Membrane Preparation

Chinese hamster ovary cells were cultured  (CHO) that stably express the cannabinoid receptor recombinant human 1 in a mixture of Ham F12 nutrients supplemented with 10% fetal bovine serum inactivated with the heat, 2 mM L-glutamine, 50 U / ml penicillin, 50 U / ml streptomycin and 0.5 mg / ml geneticin. With the purpose of to obtain cells, the culture flasks were washed twice with phosphate buffered saline and scratched. TO then the cells were collected by centrifugation (200 x g, 10 minutes) and stored dry at -80 ° C. The cells homogenized in ice cold 20 mM HEPES, 10 mM EDTA (pH 7.5) and centrifuged at 40,000 x g for 15 minutes at 4 ° C. He pellet was resuspended in 20 mM HEPES, 0.1 mM EDTA (pH 7.5) and centrifuged for 15 minutes at 4 ° C. The final pellet was resuspended in 20 mM HEPES, 0.1 mM EDTA (pH 7.5) and divided into parts aliquots and stored at -80 ° C until use.

[35 S] GTPγS binding assay

The reaction was performed in 96-well plates. The membranes were incubated (15 µg / well) for 60 minutes at 30 ° C in buffer (50 mM HEPES, 100 mM KCl, 5 mM MgCl2, EDTA 1 mM, 0.1% w / v bovine serum albumin, 5 µM GDP, saponin (10 µg / ml), [35 S] 0.5 nM GTPγS, pH 7.4) with a  compound at a final concentration of 1 µM in the absence or presence of an agonist dose-response curve WIN 55,212-2 between 3 nM and 3 µM. Incubation It was terminated by rapid filtration through fiberglass FB Millipore Multiscreen and rinsed twice with buffer ice cold test. The filtering plates were dried and dried. They added 30! to the scintillation liquid. The radioactivity is determined using Wallac Microbeta Trilux. Each experiment is performed at least in duplicate. A systematically performed dose-response of WIN 55,212-2 alone or in the presence of Rimonabant (1 µM).

Calculations

The average union of [35 S] GTP? Baseline was subtracted from all data of Union. In order to compare the results of antagonism of one screening group with respect to another, the difference between the maximum agonist effect of Win 55,212-2 alone and the maximum antagonism effect due to WIN 55,212-2 more Rimonabant (1 µM) was defined as 100%.

Additional methods Alcohol intake

The following protocol can be used to assess the effects of alcohol intake on female rats (for example, bred at the University of Indiana) who prefer alcohol with an extensive history of drinking. The following reference provides a detailed description of rats P: Lumeng, L. et al ., "Different sensivities to ethanol in alcohol-preferring and non-prefering rats," Pharmacol, Biochem Behav., 16, 125-130 (1982).

Female rats were given two hours of access to alcohol (10% v / v and water, choice of two bottles) daily at the beginning of the dark cycle. The rats are kept in a reverse cycle to facilitate experimental interactions. To the animals were initially assigned four groups matched to alcohol intakes: Group 1- vehicle; Group2 - control positive (for example, 5.6 mg / kg AM251; Group 3 - low dose of candidate compound; and Group 4 - high dose of candidate compound. Test compounds are generally mixed in a vehicle of 30% cyclodextrin (w / v) in distilled water at a volume of 1-2 ml / kg Vehicle injections are provided to all groups during the first two days of experiment. Then for 2 days they are provided drug injections (to the appropriate groups) and a final day of vehicle injections On the days of drug injection, the drugs are provided sc 30 minutes before a period of Access to alcohol for 2 hours. Alcohol intake for all animals are measured during the trial period and a comparison between animals treated with drug and animals treated with vehicle to determine the effects of the compounds in the behavior in the drink of alcohol.

Additional drinking studies can be performed using C57BI / 6 female mice (Charles River). Several studies have shown that this breed of mice will easily consume alcohol requiring little or no manipulation (Middaugh et al ., "Ethanol Consumption by C57BU6 Mice: Influence of Gender and Procedural Variables" Alcohol, 17 (3), 175-183, 1999; Le et al ., "Alcohol Consumption by C57BL / 6, BALA / c and DBA / 2 Mice in a Limited Access Paradigm" Pharmacology Biochemistry and Behavior, 47, 375-378, 1994).

For example, upon arrival, the mice will placed individually and provided with unlimited access to powdered rat food, water and a 10% alcohol solution (p / v). After 2-3 weeks of unlimited access, water is limited for 20 hours and alcohol is limited to only 2 daily access hours. This is done in a way that the access period was the last 2 hours of the dark part of the light cycle

Once the behavior stabilizes with the Drink, you can start the tests. Mice are considered stable when the average alcohol consumption for 3 days is 20% of the average for the 3 days. Day 1 of trial consists in which all mice receive the vehicle injection (sc or ip). Thirty to 120 minutes after the injection Provides access to alcohol and water. The consumption of alcohol for that day (g / kg) and are assigned to a group, so that All groups have an ambiguous alcohol intake. In the days 2 and 3, the vehicle or drug mice are injected and the Same protocol as the previous day. On day 4 they rinse and don't know They provide injections. The data is analyzed using repeated ANOVA measurements. The change in water consumption or Alcohol is compared to the vehicle for each day of the test. The positive results would be interpreted as a compound that was able to significantly reduce alcohol consumption without having Water effects

Methods of oxygen consumption

Total oxygen consumption in the body is measured using an indirect calorimeter (Oxymax of Columbus Instruments, Columbus, OH) in male Sprague Dawley rats (if another breed of female rat or female rat is used, it will be specified). The rats (for example 300-380 g of body weight) are placed in calorimeter chambers and the chambers are placed in activity monitors. These studies are carried out during the light cycle. Before measuring oxygen consumption, rats are fed with standard food ad libitum . During the measurement of oxygen consumption, food is not available. Baseline pre-dose oxygen consumption and mobile activity are measured every 10 minutes for 2.5 to 3 hours. At the end of the baseline pre-dosing period, the chambers are opened and the animals are given a single dose of compound (the normal dosage range is 0.001 to 10 mg / kg) by oral gavage (or other route of administration as specified, i.e. sc, ip, iv). The drugs are prepared in methylcellulose, water or other specified vehicle (examples include PEG400, 30% beta-dextran cycle and propylene glycol). Oxygen consumption and mobile activity are measured every 10 minutes for an additional period after dosing for 1 to 6 hours.

The Oxymax calorimeter software calculates the oxygen consumption (ml / kg / h) based on the flow rate of air through the cameras and the difference in the content of oxygen at the input and output ports. The monitors of activity have 15 infrared light beams spaced on each axis for an inch, mobile activity is recorded when you do two Consecutive are broken and the results are recorded as counts

Oxygen consumption at rest during the before and after dosing period, is calculated by the average of the O2 consumption values in 10 minutes, excluding periods of high mobile activity (count of mobile activity> 100) and excluding the first 5 values of the pre-dosing period and the first value of the post dosing period. The change in consumption of oxygen is indicated as a percentage and is calculated by dividing the resting oxygen consumption after dosing between pre-dosing oxygen consumption * 100. The Experiments will usually be performed with n = 4-6 rats and the results are indicated as mean +/- SEM.

Interpretation

An increase in oxygen consumption greater than 10% is considered a positive result. Historically, the rats treated with vehicle do not suffer changes in the consumption of oxygen compared to baseline pre-dose.

Nicotine dependence

A model of the preference of the model or site for intravenous nicotine self-administration can be used to assess the effects of a candidate compound on nicotine dependence (see, for example, Vastola, et al ., Physiol. Beba. 77: 107-114, 2002; Brower, et al ., Brain Res. 930: 12-20, 2002).

Place preference

Sprague-Dawley rats are used in the study (Vastola, et al ., 2002). The animals are placed in a lighting cycle 12 h / 12 h with the temperature controlled with an ad libitum access to food and water. Conditioning and testing are performed in a chamber divided into two compartments with a door separating the two compartments. The behavior of animals is recorded by camcorder.

Animals are accustomed to the injection process  during several days. Then the animals are placed in the test chamber with free access to both compartments. Be determines the initial preference for a particular compartment. For conditioning tests, nicotine is injected into animals and are restricted to the non-preferred compartment, or injects saline into animals and are restricted to preferred compartment. On the day of the test, the door that separates the compartments, the animal is placed in the center of the chamber and let it move freely between compartments The time spent in each compartment is noted. The preferential occupation of the nicotine compartment follows the Conditioning booster effects of nicotine.

Self-administration

Self-administration in animals is a predictor of a potential abuse of a compound in humans. The modifications to this procedure can also be used to identify compounds that prevent or block the Drug booster properties that have potential abuse. A compound that eliminates the self-administration of a drug can prevent drug abuse or its dependence.

Sprague-Dawley rats are used in this study. Initially, the animals are placed in a lighting cycle of 12 h / 12 h with controlled temperature and ad libitum access to food and food. Next, jugular catheters that exit through the animal's back are implanted in the animals, and each animal is placed in an individual operating chamber (Brower, et al ., 2002). The catheters are connected to a computer-driven syringe pump that is located outside the chamber. The camera contains two levers with a green light located on each lever. The light illuminates when nicotine is available.

In a self-administration test, the animals are placed in the operating chambers and the levers are randomly designated as an active and inactive lever. Every Active lever response produces an infusion of nicotine. The pressure on the inactive lever has no effect, but it also register. The animals are then trained for self-administration of nicotine during an established period of time by accessing a drug during each daily session. The illumination of the camera housing light indicates the session start and nicotine availability. When the session ends off. Initially, an infusion of Nicotine with each active lever pressure. Once it has established the pressure behavior on the lever, it increases the number of pressures to produce an infusion of nicotine. After obtaining a stable self-administration of nicotine, the effect of a candidate compound can be evaluated about nicotine booster behavior. The administration of this candidate compound before the session I could enhance, extinguish or produce any change in the behavior of the self-administration The tests are done every two days and are controls the order of administration of the candidate compound.

Alzheimer's / dementia experiments Morris Water Maze Task

The Morris water maze is an in vivo behavior test to measure learning and memory of spatial orientation through a complex learning task. It is very suitable for test compounds that increase learning and memory. A circular tank or pool (diameter 2 m, height 0.7 m) is filled with water and a 10 cm 2 platform 1-1.5 cm below the water surface is placed in a defined position within from the pool. The escape platform is not viable for an animal that swims in the water tank. For the experiment, a rat or mouse is placed in the pool to swim freely.

Animals have the task of locating the submerged platform i the time and distance required are measured For your satisfactory recovery. Multiple are available external indicators to the maze through the furniture of the room, including tables, computer equipment, a second tank of water, the presence of the experimenter and through a radio on A bookshelf that sounds soft.

Before compound administration candidate, animals are trained in the task 4 times a day For 5 days. Test compounds are administered orally or intraperitoneally on the day of the experiment in a while defined (for example, 30 minutes before the first test of I swim). Control animals are dosed with the corresponding vehicle that does not contain candidate compound. The compounds assets produce shorter times and distances to locate the platform (that is, the better the animal remembers the platform location, the shorter the covered distance and more quickly reach the platform).

The test can also be carried out. using transgenic or cognitively impaired animals. He cognitive impairment is induced by advanced age or experimentally by brain injuries, such as injuries Bilateral entorhinal cortex in rats. These injuries are they can induce by intracerebral injections of the acid Ibotenic excitotoxin.

Object Recognition Task

The object recognition task is used to evaluate the effects of compounds on performance cognitive rodents. A rat is placed in an open field, in which two identical objects are placed. Rats inspect both objects during the initial test of the test. After certain retention interval (for example, 24 hours), is performed A second test. Here, one of the two objects used in the first test (the "familiar" object) and a new object is placed in the open field and the inspection time is measured in Each of the objects. Good retention is reflected by longer scan times to the new object in comparison with the "familiar" object.

The administration of the cognitive enhancer Putative prior to the first test allows predominantly the evaluation of the effects of acquisition and in the processes of consolidation. Administration of the candidate compound after the first test allows the evaluation of the effects on consolidation processes while administration before the second test allows to measure the effects in processes of Recovery.

Passive Avoidance Task

The passive avoidance task evaluates the memory performance in rats and mice. Avoidance inhibitor uses an apparatus consisting of a box with two compartments separated by a door with guillotine that can Be manipulated by the experimenter. A compartment is illuminated with bright light and the other compartment is dark. A 2 cm threshold separates the two compartments when the door with Guillotine rises 15 cm. When the door opens, the lighting in the dark compartment it is about 2 lux. The Light intensity is approximately 500 lux in the center of the floor of the compartment with light.

Two habitation sessions are provided, one  shock session and a retention session, separated by 24 hour session intervals. During the sessions of habituation and retention session, the rat is allowed to explore the device for 300 seconds. The rat is placed in the compartment with light, facing the wall opposite the door in guillotine shape After an accommodation period of 15 seconds, the door is opened with a guillotine, so that all Parts of the device can be visited freely. The rats normally avoid brightly lit areas and They will enter the dark compartment in a few seconds.

In the shock session, the door with guillotine between the compartments, get off as soon as the rat has entered the dark compartment with all the legs and it administers a shock on the 1 mA legs for 2 seconds. TO then the rat is removed from the apparatus and returned to its cage. The procedure during the retention session is identical to the habituation sessions.

Latency of inhibitory avoidance ("step-through)", that is, the first latency entry into the dark compartment (in seconds) during retention session is an index of the memory performance of the animal: a better retention is presumed if the latency to enter in the dark compartment is larger. A compound is provided candidate 30 minutes before the shock session along with 1 mg / kg of scopolamine. Scopolamine impairs the performance of the memory during the retention session 24 hours later. If he candidate compound increases input latency compared with controls treated with scopolamine, it is considered that It has an activity that enhances cognition.

Spontaneous alternation task in labyrinth T

The task of spontaneous alternation in the T-shaped labyrinth (TeMCAT) values the performance of the spatial memory in mice. The starting arm and the two arms T-shaped labyrinth objectives are arranged with doors with guillotines that can be manually manipulated by the experimenter. A mouse is placed on the starting arm at the beginning of training In the first test, the target arm left or right lock down the respective door with guillotine (forced test).

After the mouse has been released from starting arm, explore the maze, finally entering the  open target arm, and will return to the starting position, where will be confined for 5 seconds when lowering the door with guillotine. Then the animal can freely choose between the left and right target arm (all doors with guillotine open) for 14 additional tests (tests of free choice). As soon as a mouse has entered an arm objective, the other arm closes. The mouse finally returns to starting arm and is free to visit any arm you want after being confined to the starting arm for 5 seconds. After completing the 14 free choice tests in One session, the animal is extracted from the maze.

Alternations are calculated as a percentage of The 14 tests. This percentage and the total time are analyzed necessary to complete the first forced test and the subsequent 14 tests of free choice (in seconds). In addition, the Cognitive deficits can be induced by injecting scopolamine 30 minutes before the start of the session training. A cognition enhancer, administered before from the start of the training session, it will antagonize at least partially, the reduction induced by scopolamine in the rate of spontaneous alternation.

Depression model

A forced swim or tail suspension model can be used to assess the efficacy of antidepressant compounds (see, for example, Prosolt et al ., Nature 266: 730-732, 1977; Stem et al ., Psychopharmacology 85: 367 -370, 1985).

Forced swim test

Rats or mice are placed in a cylinder full of water at 23-25 ° C which is not possible escape. Initially, the animals fight and try to escape, but finally they adopt a characteristic stationary posture and not they make more attempts to escape except for small movements necessary of their heads above the water. The doses are dosed animals with a compound and an observer measures the activity (swimming or climbing) or immobility. The immobility is considered by some as the reflection of a "despair of behavior "in which animals stop fighting for Escape the adverse situation. A wide range of Clinically used antidepressants (TCAs, MAOIs, SSRIs, atypical) decrease mobility in this test and present a good predictive validity in the fact that it detects antidepressants with different mechanisms of action, but its theoretical validity is weak. Pharmacologically selective antidepressant drugs produce at least two active behavior patterns different. Selective serotonin reuptake inhibitors increase swimming behavior while drugs which act primarily to increase extracellular levels Norpinephrine or dopamine increase the climbing behavior. There are false positives (psychostimulants), but relatively few false negatives (agonists [beta] -adrenergic). The test is sensitive. muscle relaxants (benzodiazepines) and sedative effects (neuroleptics) leading to greater immobility. Fake positives and false negatives can be screened frequently by measuring whether the compound produces stimulation or Locomotive sedation.

Tail suspension test

When suspended by the tail, mice initially they will fight and try to escape and then they will alternate between active attempts to escape and immobility. In this test, the animals are dosed with a compound and a Observer measures immobility for 6 minutes. Porsolt describes still behavior as the "despair of behavior "in which animals stop fighting for Escape the adverse situation. A wide range of clinically used antidepressants (tricyclics, MAOIs, SSRIs and atypical) reduce immobility in this model. The test has good predictive validity for antidepressant activity and It works for most classes of antidepressants but including some false positives (psychostimulants). The proof It is sensitive muscle relaxants (benzodiazepines) and effects sedatives (neuroleptics) leading to greater immobility. The false positives and false negatives can be screened frequently by measuring whether the compound produces locomotive stimulation or sedation. In mice they have been observed differences between races in the tail suspension. The test of tail suspension has some apparent validity but its theoretical validity is quite weak.

Schizophrenia Model

An inhibition model can be used by prepulse to assess the efficacy of antipsychotic compounds (See Swerdlow and Geyer, Schizophrenia Bulletin 24: 285-301, 1998).

Prepulse Inhibition

Prepulse inhibition is the process whereby a relatively soft stimulus, the prepulse, suppresses the response to a strong stimulus to obtain startles when the prepulse precedes the stimulus of fright for a short duration (approximately 10 to 50 milliseconds) Prepulse inhibition is a phenomenon of cross species (that is, it is present in mammals that vary from mice to humans), although it is relatively absent among schizophrenic patients It is believed that the PPI deficit in schizophrenic patients reflects the loss of shock sensoromotor that can lead to a sensory flood and cognitive fragmentation In this test, mice or rats are they are administered compounds and placed individually in a vessel on a transducer platform to measure the startle of the whole body. The container is located in a startle camera with a white background noise. Ras a brief habituation period, animals undergo multiple tests of a weak auditory prepulse stimulus, followed by a stimulus of loud auditory shock. Four types of test apply: pre-pulse more startle, pre-pulse alone, startle alone, and without stimulation PPI is measured as the amount of inhibition of startle after prepulse and is expressed as the percentage of basic shock. As a control, measurements are taken in the tests no stimulation and prepulse alone. The PPI is considered to be a test with a good predictive, apparent and theoretical validity for the  schizophrenia. Putative antipsychotics can be tested alone to determine if they increase the PPI. Alternatively, they can be screen antipsychotics to determine if they block multiple agents that interrupt the PPI (apomorphine, d-amphetamine, PCP, ketamine, DOI). Finally, mutant mice with or without Drugs can be screened using the PPI procedure.

Anxiety model

A raised maze model can be used cross to assess the efficacy of anxiolytic compounds (see Pellow and File, Pharm. Biochem Drink 24, 525-529, 1986).

Labyrinth raised in cross

The raised labyrinth is used widely as a paradigm of anxiety that examines the conflict between the impulse to explore and the aversion to heights and open spaces of rats and mice. The labyrinth it is a cross formed with two open arms and two closed arms They rise on the base. It is believed that the combination of light, the open arms and height produce fear or anxiety responses Unconditioned in mice and rats. The test apparatus is a maze with open top of opaque plastic with alternating open and closed arms. For rats, each arm It is 45-55 cm in length and 8-12 cm wide, with the faces of the arms closed of 35-45 cm high, the board about 10 x 10 cm, and the labyrinth rises 45-55 cm by above ground. The raised cross maze for mouse consists in two closed arms (15 x 6 x 30 cm) and two open arms (1 x 6 x 30 cm) forming a cross, with a quadrangular center (6 x 6 cm). The labyrinth is 50 cm above the ground. Essay It is done in a room without noise or distractions. In the test days, the animals are given drug or vehicle. If a pretreatment period is necessary, the animals are returned to the cage for the duration of the pretreatment; otherwise, the animals are placed in a chamber that contains a clear plastic individually or with other cage mates for 1-10 minutes before from the moment of rehearsal. Then the rats are placed in the center of the maze always oriented in the same direction, constantly facing an open arm or a closed arm. For 5-10 minutes, the entries in each arm and the time spent in each arm is recorded by the observer or observers or via videotape or a receiving computer data from a camcorder mounted on the maze. For what count as input, all four legs must be inside the arm. If necessary, additional measurements of anxiety-related behavior, that is, time they spend without movement, time they spend in the center, time that they touch each other and the number of stands ("rears"), stretching postures or stool produced. After the rehearsal, The animals are returned to the cages. When the animals get placed in the center of the maze, spend most of the time in closed arms avoiding open arms. Drugs Anxiolytics, such as benzodiazepines, will increase the amount of time that animals spend in open arms. Essay It is also sensitive to angiogenic drugs that provide a great support for its predictive validity.

Erectile dysfunction

Drugs that affect erectile function can be tested by measuring the effect on the increase in cavernous pressure caused by apomorphine in the awake rat, as described by Anderson, et al ., (J. Urol. 161: 1707-1712 , 1999). One end of a polyethylene tube is implanted in the cavernous space of the male Sprague-Dawley rat penis. After recovery from surgery, intracavernous pressure is recorded using a transducer connected to a multichannel pen-shaped recorder. Erections are induced by the administration of apomorphine (150-250 µg / kg sc) with or without candidate compound, and the results are compared for the treated group and the untreated group.

Female sexual dysfunction

Systems for testing compounds for the treatment of female sexual dysfunction include in vitro and in situ models that use vaginal or clitoral smooth muscle preparations, histological evaluation, and vaginal blood flow evaluation. In vivo studies of sexual responses focus on behavioral paradigms that involve lordotic posture and receptivity, as well as motivation indices using a step-by-step method in dual cameras. (See, for example, Hale, et al ., Int. J. Impot. Res. 15 Suppl 5: S75-79, 2003).

The present invention is illustrated below. With the help of examples. These illustrations are provided by way of example only and do not limit the general spirit of the present invention

       \ vskip1.000000 \ baselineskip
    

Examples Example 1 Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

       \ vskip1.000000 \ baselineskip
    

38

       \ vskip1.000000 \ baselineskip
    

It dissolved piperidin-1-yl-amide of the acid 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic (1 mmol) in chloroform (20 mL) and iodide of slowly added methyl (3 mmol). The mixture was heated at reflux for 72 hours, excess methyl iodide was evaporated and the residue crystallized ethanol crude (5 mL) and a small amount of diethyl ether to provide the title compound as a yellow solid.

m.p. 174-176 ° C

FTIR (KBr, cm -1) 3448, 2948, 1675, 1480, 1248, 1116, 824 1 H-NMR (400 MHz, METHANOL- d 4) δ ppm 1.66 (m, 1 H) 1.91 (m, 3 H) 2.05 (m, 2 H) 3.26 (dd, J = 17.98, 6.64 Hz, 1 H) 3.67 (m, 2 H) 3.70 (s, 3 H) 3.74 (dd, J = 17.98, 12.50 Hz, 1 H) 4.45 (d, J = 12.90 Hz, 1 H) 4.57 (d, J = 12.50 Hz, 1 H) 5.94 (dd, J = 12.50, 6.64 Hz, 1 H) 7.22 (m , 5 H) 7.36 (d, J = 2.34 Hz, 1 H) 7.41 (d, J = 8.79 Hz, 1 H.

The following examples 2 to 50 were prepared according to the procedure described for the synthesis of example 1. The  Those skilled in the art are familiar with the materials of heading needed to obtain said compounds.

       \ vskip1.000000 \ baselineskip
    

Example 51 N-piperidinyl N-oxide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydropyrazol-3-carboxamide

Under nitrogen gas as an inert atmosphere, it dissolved N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide (0.15 g, 0.33 mmol) in 7 ml of dichloromethane. The solution resulting was cooled on ice to 0 ° C and acid was added m-chloroperbenzoic acid (0.204 g, 0.83 mmol) in several portions. After stirring for 15 minutes, a control to through thin layer chromatography showed that there was no starting material present. Then it was added slowly a saturated solution of sodium bicarbonate, the phase was separated organic, washed with water, dried over sodium sulfate and filter. The filtered solution was evaporated to dryness and the crude product was purified by column chromatography producing 78 mg (50% of theoretical yield) of the N-oxide of N-piperidinyl 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydropyrazol-3-carboxamide in the form of a white solid that has a melting point of 115-120 ° C.

IR (KBr, cm -1): 3202, 1678, 1654, 1474, 1309, 1107.

1 H NMR (CDCl 3, δ): 1.6 (m, 3H), 1.8-2.0 (m, 4H), 2.55 (m, 2H), 3.3 (dd, J = 6.3 Hz and 18.2 Hz, 1H), 3.7 (m, 3H), 5.8 (dd, J = 6.3 Hz and 12.5 Hz, 1H), 7.0-7.3 (m, 7H), 8.5 (s, 1H).

39

40

41

42

43

44

Four. Five

46

       \ vskip1.000000 \ baselineskip
    

Pharmacological data

The binding data for some of the compounds of the invention of general formula I were obtained as and as described in the Pharmacological Methods section, part I and they are shown in the following table (table 1).

       \ vskip1.000000 \ baselineskip
    

47

Claims (33)

1. Quaternary ammonium salt of general formula I, 48 in the that

X

it's O or S;

TO

represents a hydrogen atom or a radical unsubstituted or at least monosubstituted alkyl;

R1 and R2, independently of each other, they represent in each case a

quad

aryl or heteroaryl radical, unsubstituted or at less monosubstituted, which may be condensed with a system monocyclic or polycyclic, unsubstituted or at least monosubstituted;

quad

or a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be connected to a bridge by at least one unsubstituted alkylene group or at least monosubstituted;

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

quad

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted,

quad

a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which optionally contains the less a heteroatom as a ring member, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a alkylene group, an alkenylene group or an alkynylene group, not substituted or at least monosubstituted and / or may be linked with a  bridge by at least one unsubstituted alkylene group or at less monosubstituted;

quad

an aryl or heteroaryl radical, unsubstituted or at less monosubstituted, which may be condensed with a system cyclic mono or polycyclic, unsubstituted or at least monosubstituted and / or it can be linked through an alkylene group, a group alkenylene or an alkynylene group, unsubstituted or at least monosubstituted;

a moiety -O-R 7; a rest -S-R 8; a moiety -NH-R9 or a moiety -NR 10 R 11; R 5 and R 6, independently of each other, they represent in each case an atom of hydrogen;

quad

a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted;

or R 5 and R 6 together with the nitrogen atom that bridges form a ring heterocyclic unsubstituted or at least monosubstituted, saturated or unsaturated, which may contain at least one additional heteroatom as a ring member and / or which may be condensed with one or two  monocyclic or polycyclic cyclic systems, optionally at least monosubstituted; R 7, R 8, R 9, R 10 and R 11 independently of each other, in each case represent a saturated or unsaturated aliphatic radical, unsubstituted or at least monosubstituted,

quad

a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which optionally contains the less a heteroatom as a ring member, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a alkylene group, an alkenylene group or an alkynylene group, not substituted or at least monosubstituted and / or may be linked with a  bridge by at least one unsubstituted alkylene group or at less monosubstituted;

quad

or a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a alkylene group, an alkenylene group or an alkynylene group, not substituted or at least monosubstituted and / or may be linked with a  bridge by at least one unsubstituted alkylene group or at less monosubstituted;

quad

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate no substituted or at least monosubstituted, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

49

quad

Y

\ vocalinvisible

\ invisible text

R 12 and R 13, independently of each other, they represent in each case a radical saturated or unsaturated aliphatic, unsubstituted or at least monosubstituted;

quad

an aryl or heteroaryl radical, unsubstituted or at less monosubstituted, which can be linked through a group alkylene, unsubstituted or at least monosubstituted

quad

or a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which optionally contains at least one heteroatom as a ring member, which may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted and / or may be attached to through an unsubstituted alkylene group or at least monosubstituted;

quad

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

2. Salt according to claim 1, characterized in that

X

it is O or S;

TO

represents a hydrogen atom or a radical C 1-10 alkyl unsubstituted or at least monosubstituted;

R1 and R2, independently of each other, they represent in each case a radical 6 or 10-membered aryl unsubstituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic, unsubstituted or at least monosubstituted;

quad

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted;

quad

a C 3-16 cycloalkyl radical or an unsubstituted C 4-16 cycloalkenyl radical or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, not substituted or at least monosubstituted and / or can be joined by a bridge by at least one alkylene group C_ {1-5} unsubstituted or at least monosubstituted;

quad

or a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

quad

a C 1-16 alkyl radical, a C 2-16 alkenyl radical or an alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

quad

a C 3-16 cycloalkyl radical or an unsubstituted C 4-16 cycloalkenyl radical or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, not substituted or at least monosubstituted and / or which can be joined by a C 1-5 alkylene group, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

quad

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or which can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

quad

a 6 or 10-membered aryl radical, unsubstituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

quad

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least  monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted;

a moiety -O-R 7; a remainder-S-R 8; a rest -NH-R 9 or a moiety -NR 10 R 11; R 5 and R 6, independently of each other, they represent in each case an atom of hydrogen;

quad

a C 1-16 alkyl radical, C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

or

quad

R 5 and R 6 together with the nitrogen atom which bridges form a heterocyclic ring from 4 to 10 unsubstituted or at least substituted, saturated or unsaturated, which may optionally contain 1, 2 or 3 additional heteroatom (s) selected from the group consisting of sulfur, nitrogen and oxygen as ring member (s) and / or that may be condensed with one or two monocyclic or polycyclic cyclic systems, optionally at less monosubstituted;

R 7, R 8, R 9, R 10 and R 11, independently of each other, they represent in each case

quad

a C 1-6 alkyl radical, a C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted;

quad

a C 3-16 cycloalkyl radical or an unsubstituted C 4-16 cycloalkenyl radical or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or that can be joined by a group C 1-5 alkylene, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

quad

a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or which can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted;

quad

an unsubstituted 6 or 10-membered aryl radical or at least monosubstituted, which may be condensed with a system cyclic, mono or polycyclic, unsubstituted or at least monosubstituted, and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

quad

or a heteroaryl radical of 5 to 14 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted;

quad

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate no substituted or at least monosubstituted, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

fifty Y R 12 and R 13, independently between yes, they represent in each case

quad

a C 1-6 alkyl radical no substituted or at least monosubstituted, an alkenyl radical C 2-16 or an alkynyl radical C 2-16;

quad

an unsubstituted 6 or 10-membered aryl radical or at least monosubstituted, which can be linked through a group C 1-5 alkylene unsubstituted or at least monosubstituted;

quad

a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be attached to through a C 1-5 alkylene group no substituted or at least monosubstituted, an alkenylene group C 2-5 or an alkynylene group C 2-5;

quad

a C 3-16 cycloalkyl radical or an unsubstituted C 4-16 cycloalkenyl radical or at least monosubstituted, which in each case can be attached through a C 1-5 alkylene group no substituted or at least monosubstituted and / or can be joined by a bridge by at least one alkylene group C_ {1-5} unsubstituted or at least monosubstituted;

quad

or a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which in each case can be linked through a C 1-5 alkylene group unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted;

in which

quad

the rings of the cyclic system mentioned previously they are, in each case independently of each other, of 5, 6 or 7 members and can, in each case independently of each other, optionally contain 1, 2 or 3 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur;

quad

the heteroaryl radicals mentioned above,  in each case, they optionally contain 1, 2, 3 or 4 heteroatom (s) selected regardless of group consisting of nitrogen, oxygen and sulfur as a member ring bro (s);

quad

heterocycloalkyl radicals and radicals heterocycloalkenyl mentioned above, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur as a member (s) of ring;

quad

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

3. Salt according to claim 1 or 2, characterized in that A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl , n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2 -octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected
regardless of the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH_ {3} 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH_ { 3}, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S -CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, -CN and -NO 2. 4. Salt according to one or more of claims 1 to 3, characterized in that R1 and R2, independently of each other, in each case represent a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, quinolinyl, quinolinyl benzo [b] thiophenyl, benzo [2,1,3] thiadiazolyl, [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 6 5 substituent (s) independently selected from the group consisting of -CF 3, - CH 2 -Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3 , -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH_ { 2} -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, -S-CH 3, -S-C 2 H 5 , -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3,
-SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C 2 } H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH_ {3 }, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH -CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, phenoxy and thiophenyl, wherein said thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl;

quad

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydrofuranyl, (2,5) -dihydrothiophenyl, (2,3) -dihydrofuranyl, (2,3) -dihydrofuranyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4) -dihydro-2H-pyranyl, (3,4) -dihydro-2H-thiopyranyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3) -dioxanyl, (1,4) -dioxanyl, (1,3) -dioxolanyl, decahydronaphthyl, octahydro-cyclopenta [c] pyrrolyl, decahydroquinolinyl and dodecahydro-carbazolyl,

quad

which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2.

5. Salt according to one or more of claims 1 to 4, characterized in that R3 and R4, independently of each other, in each case represent H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

quad

a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which can be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) independently selected from the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN and -NO 2;

quad

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH 2) - (CH 2) - (CH 2) - or -CH = CH and / or that may be optionally substituted with 1, 2, 3, 4 or 5 selected substituent (s) regardless of the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) -, - (CH 2) - (CH 2) - (CH 2) - or -CH = CH and / or that may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11.

         \ vskip1.000000 \ baselineskip
      

6. Salt according to one or more of claims 1 to 5, characterized in that R 5 and R 6, independently of each other, in each case represent a hydrogen atom;

quad

or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected of the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, -CN and -NO_ {2}.

7. Salt according to one or more of claims 1 to 5, characterized in that R 5 and R 6 together with the bridging nitrogen atom form a moiety selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, (1,2 , 3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro- 4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, indolinyl, isoindolinyl, (1,2,3,4) -tetrahydroquinolinyl, (1,2,3,4) -tetrahydroisoquinolinyl, octahydro-cyclopenta [ c] pyrrolyl, (1,3,4,7,9a) -hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a) -hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7) -dihydro-4H-thieno [3,2-c] pyridinyl, (2,3) -d ihydro-1H-benzo [de] isoquinolinyl and (1,2,3,4) -tetrahydroquinoxazolinyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting in oxo (= O), thioxo (= S), -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl , n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH_ { 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3,
-OC (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O -CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH_ {3} 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S- C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 - CH 2 -CH 2 -CH 3, -SC (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3 , -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO, -C (= O) -CH 3, -C (= O) -C_ { 2 H 5, -C (= O) -C (CH 3) 3,
-C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -OC ( CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3,
-C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH 3, -S (= O) -C 2 } H 5, -S (= O) -C 3 H 7,
-S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C_ { 2 H 5) 2, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl. 8. Salt according to one or more of claims 1 to 7, characterized in that R 7, R 8, R 9, R 10 and R 11 independently of each other, they represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (O 2 H 5) 2, -CN and -NO 2;

quad

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bike [3.2.1] octyl and diazepanyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) - N (O 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -O 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (O 2 H 5) 2;

quad

or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group that consists of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2.

9. Salt according to one or more of claims 1 to 8, characterized in that B represents an anion selected from the group consisting of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate which may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting in F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate, 51 10. Salt according to one or more of claims 1 to 9, characterized in that R 12 and R 13, independently of each other, in each case represent a radical selected from the group consisting of methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n- hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl; which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected independently from the group consisting of F, Cl, Br, -NH2, - NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, benzimidazolyl, isoquinolinyl and pyrazolyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) - or - (CH 2) - (CH 2) - (CH 2) and / or may be substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -CF_ {3}, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -SO 3 H, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2 and phenyl;

quad

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo [2.2.1] heptyl, which may be attached through of a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) and / or may optionally be substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2.

         \ vskip1.000000 \ baselineskip
      

11. Salt according to one or more of claims 1 to 10, characterized in that

quad

X is O or S:

quad

A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3,  -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, -CN and -NO2;

quad

R1 and R2, independently of each other, they represent in each case a radical selected from the group that consists of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3] thiadiazolyl, [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzoisoxazolyl, benzisothiazolyl e imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of group consisting of -CF 3, -CH 2 -Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3,  -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) - N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, phenoxy and thiophenyl, in the that the thiophenyl radical may be substituted with 1, 2 or 3 substituent (s) independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl.

quad

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl,  diazepanyl, azocanyl, (2,5) -dihydrofuranyl, (2,5) -dihydrothiophenyl, (2,3) -dihydrofuranyl, (2,3) -dihydrofuranyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, tetrahydrothiopyranyl, tetrahydropyranyl, (3,4) -dihydro-2H-pyranyl, (3,4) -dihydro-2H-thiopyranyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, (1,3) -dioxanyl, (1,4) -dioxanyl, (1,3) -dioxolanyl, decahydronaphthyl, octahydro-cyclopenta [c] pyrrolyl, decahydroquinolinyl and dodecahydro-carbazolyl, which can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH- C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

R 3 and R 4, independently of each other, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

quad

a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which can be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected regardless of group consisting of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN and -NO 2;

quad

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group that consists of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3,  -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl and diazepanyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11;

quad

R 5 and R 6, independently of each other, they represent in each case a hydrogen atom;

quad

or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl and 4-octyl, which can be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of group consisting of -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, -CN and -NO2;

quad

or

quad

R 5 and R 6 together with the nitrogen atom which acts as a bridge form a remainder selected from the group that consists of pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, azepanyl, diazepanyl, azocanyl, (2,5) -dihydro-1H-pyrrolyl, (2,3) -dihydro-1H-pyrrolyl, (1,2,3,6) -tetrahydropyridinyl, (1,2,3,4) -tetrahydropyridinyl, (1,2,5,6) -tetrahydropyridinyl, [1,3] -oxazinanyl, hexahydropyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, (5,6) -dihydro-4H-pyrimidinyl, oxazolidinyl, indolinyl, isoindolinyl, (1,2,3,4) -tetrahydroquinolinyl, (1,2,3,4) -tetrahydroisoquinolinyl, octahydro-cyclopenta [c] pyrrolyl, (1,3,4,7,9a) -hexahydro-2H-quinolizinyl, (1,2,3,5,6,8a) -hexahydro-indolizinyl, decahydroquinolinyl, dodecahydro-carbazolyl, 9H-carbazolyl, decahydroisoquinolinyl, (6,7) -dihydro-4H-thieno [3,2-c] pyridinyl, (2,3) -dihydro-1H-benzo [de] isoquinolinyl and (1,2,3,4) -tetrahydroquinoxazolinyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3 r -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl;

quad

R 7, R 8, R 9, R 10 and R 11 independently of each other, they represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl, which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group that consists of -OH, F, Cl, Br, I, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2, -CN and -NO 2;

quad

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, aziridinyl, azetidinyl, imidazolidinyl, thiomorpholinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, 8-aza-bike [3.2.1] octyl and diazepanyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) - N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

or a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl and isoindolyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) - or -CH = CH and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group that consists of -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) - CH 3, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate which may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

52

quad

Y

quad

R 12 and R 13, independently of each other, they represent in each case a radical selected from the group that It consists of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, vinyl, n-propenyl, n-butenyl, n-pentenyl, n-hexenyl, ethynyl, propynyl, n-butynyl, n-pentinyl and n-hexinyl; which may be optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, -NH2, -NH-CH3, -NH-C 2 H 5, -N (CH 3) 2 and -N (O 2 H 5) 2;

quad

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, benzoimidazolyl, isoquinolinyl and pyrazolyl, which can be linked through a group - (CH2) -, - (CH2) - (CH2) - or - (CH2) - (CH2) - (CH2) - and / or may be substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -CF_ {3}, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -S-CH 3, -S-C 2 H 5, -S-CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -CF 2 H, -CFH 2, -C (= O) -NH 2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -O 2 H 5, -S (= O) 2 -C 3 H 7, -SO 3 H, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2, -N (C 2 H 5) 2 and phenyl;

quad

or a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo [2.2.1] heptyl, which may be attached through of a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2) and / or may optionally be substituted with 1, 2, 3, 4 or 5 substituent (s) selected (s) regardless of the group consisting of oxo (= O), thioxo (= S), -CF 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -O-CH 2 -O-CH 3, -O-CH 2 -CH 2 -O-CH 3, -O-CH 2 -O-C 2 H 5, -C (OCH 3) (C 2 H 5) 2, -C (OCH 3) (CH 3) 2, -CH 2 -O-CH 3, -CH 2 -O-C 2 H 5, -S-CH 3, -S-C 2 H 5, -S- CH 2 -CH 2 -CH 3, -S-CH (CH 3) 2, -S-CH 2 -CH 2 -CH 2 -CH 3, -S-C (CH 3) 3, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO_ {2}, -CHO, -C (= O) -CH_ {3}, -C (= O) -C 2 H 5, -C (= O) -C (CH 3) 3, -C (= O) -OH, -C (= O) -O-CH 3, -C (= O) -O-C 2 H 5, -C (= O) -O-C (CH 3) 3, -CF2H, -CFH2, -C (= O) -NH2, -C (= O) -NH-CH 3, -C (= O) -NH-C 2 H 5, -C (= O) -NH-C 3 H 7, -C (= O) -N (CH 3) 2, -C (= O) -N (C 2 H 5) 2, -S (= O) -CH_ {3}, -S (= O) -C 2 H 5, -S (= O) -C 3 H 7, -S (= O) 2 -CH 3, -S (= O) 2 -C 2 H 5, -S (= O) 2 -C 3 H 7, -NH 2, -NH-CH 3, -NH-C 2 H 5, -N (CH 3) 2 and -N (C 2 H 5) 2;

quad

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

12. Salt according to one or more of claims 1 to 11, characterized in that

quad

X is O or S;

quad

A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl;

quad

R1 and R2, independently of each other, they represent in each case a radical selected from the group that consists of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3] thiadiazolyl, [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl e imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of group consisting of -CF 3, -CH 2 -Cl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH 2, -OH, -SH, -NO 2, -CHO, -CF 2 H, -CFH2, phenoxy and thiophenyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituents selected regardless of the group consisting of F, Cl, Br, methyl, ethyl and n-propyl;

R 3 represents H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H;

quad

a radical selected from the group consisting of methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH,  isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl;

quad

a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which can be linked through a group - (CH2) - and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected  from the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, F, Cl and Br;

quad

a moiety -O-R 7; a rest -S-R 8, a moiety -NH-R 9 or a moiety -NR 10 R 11;

R 4

represents H or an alkyl radical selected from group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl;

R 7, R 8, R 9, R 10 and R 11, independently of each other, represent in each case a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

quad

R 5 and R 6 together with the nitrogen atom which acts as a bridge form a remainder selected from the group that consists in

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

53

         \ vskip1.000000 \ baselineskip
      

54

         \ vskip1.000000 \ baselineskip
      

55

         \ vskip1.000000 \ baselineskip
      

56

         \ vskip1.000000 \ baselineskip
      

57

         \ vskip1.000000 \ baselineskip
      

58

         \ newpage
      

quad

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, fumarate, citrate, glutarate, succinate, maleate, tartrate, phosphate, 2-oxo-glutarate, formate, acetate, propionate, lactate, gluconate, benzoate or naphthoate which may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -O-CH 3 and -O-C 2 H 5, pyruvate, ascorbate, glycolate, nicotinate, phenylacetate,

59

quad

Y

quad

R 12 and R 13, independently of each other, they represent in each case a radical selected from the group that consists of -CF 3, -C 2 F 5, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl, 3-hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-octyl, 3-octyl, 4-octyl, 2- (6-methyl) -heptyl, 2- (5-methyl) -heptyl, 2- (5-methyl) -hexyl, 2- (4-methyl) -hexyl, 2- (7-methyl) -octyl; 2- (6-methyl) -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl and n-tetradecyl;

quad

a radical selected from the group consisting of phenyl, pyridinyl, pyrazolyl, benzoimidazolyl, isoquinolinyl and naphthyl, which may be substituted with 1, 2, 3, 4 or 5 substituent (s) independently selected from the group consisting of F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH 2 -CH 3, -O-CH (CH 3) 2, -O-CH 2 -CH 2 -CH 2 -CH 3, -O-C (CH 3) 3, -OH, -NO 2, -NH 2, phenyl and -SO 3 H;

quad

a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cycloridecyl, cyclootetradecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and bicyclo [2.2.1] heptyl, which may be attached to through a group - (CH2) -, - (CH2) - (CH2) -, - (CH2) - (CH2) - (CH2);

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

13. Salt according to one or more of claims 1 to 12, characterized in that X is O; A represents a hydrogen atom or a radical selected from the group consisting of methyl, ethyl and n-propyl;

R1

represents a radical selected from the group that It consists of phenyl and thienyl (thiophenyl), which can be optionally substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, I, -O-CH 3 and -O-C 2 H 5;

R2

represents a phenyl radical, which may be substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br and I;

R 3

represents H; F; Cl; Br; I; -OH, -CN; -C (= O) -H;

quad

a radical selected from the group consisting of methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl; a benzyl radical or a residue -O-R 7;

R 4

represents H or a radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl and n-butyl;

R 5 and R 6 together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of 60 61

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

62

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

quad

R 7 represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl;

quad

B represents an anion selected from the group that It consists of chloride, bromide, iodide, fluoride, hydrogen sulfate, nitrate, dihydrogen phosphate, thiocyanate, cyanate, acrylate, methanesulfonate, ethanesulfonate, toluenesulfonate, benzenesulfonate,  (2,5) -dihydroxybenzenesulfonate, naphthalene-2-sulfonate, 5-sulfo-naphthalene-1-sulfonate, cyclamate, dodecane-1-sulfonate and (7.7) -dimethyl-2-oxo-bicyclo [2.2.1] -hept-1-yl-methanesulfonate;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

14. Salt according to one or more of the claims 1 to 13 selected from the group consisting of

[one]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- piperidinium

[2]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -4-methyl- morpholin-4-io

[3]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- azepanium

[4]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -2-methyl- octahydro-cyclopenta [c] pyrrolium

[5]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[6]

Iodide of (R) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[7]

Iodide of (S) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[8]

Iodide of 1 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-ethyl-piperidinium

[9]

Iodide of (R) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1- ethyl piperidinium

[10]

Iodide of (S) -1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- ethyl piperidinium

[eleven]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[12]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-iodo-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[13]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[14]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[fifteen]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- azepanium

[16]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[17]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-iodo-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[18]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1-methyl-azepanium

[19]

Iodide of 1 - [[5- (4-Bromo-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-pyrrolidinium

[twenty]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-fluoro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[twenty-one]

Iodide of 1 - [[2,4-Dichloro-phenyl) -5- (4-methoxy-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl- pyrrolidinium

[22]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[2. 3]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[24]

Iodide of cis-1 - [[5- (4-bromo-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[25]

Iodide of cis-1 - [[5- (4-fluoro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[26]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[27]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[28]

Iodide of trans-1 - [[5- (4-bromo-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] - amino] -1-methyl-piperidinium

[29]

Iodide of trans-1 - [[5- (4-fluoro-phenyl) -1- (2,4-dichloro-phenyl) -4-ethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[30]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl azepanium

[31]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl pyrrolidinium

[32]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl pyrrolidinium

[33]

Iodide of trans-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl azepanium

         \ newpage
      

[3. 4]

Iodide of cis-2 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[35]

Iodide of trans-2 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[36]

Iodide of 2 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,4-dimethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 2-methyl-octahydrocyclopenta [c] pyrrolium

[37]

Iodide of 2 - [[5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,4-dimethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[38]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-trifluoromethyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[39]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-methoxy-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[40]

Iodide of cis-1 - [[5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4-cyano-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] - 1-methyl-piperidinium

[41]

Iodide of 1 - [[5- (5-Chloro-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[42]

Iodide of 1 - [[5- (5-Bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[43]

Iodide of 1 - [[5- (4-Bromo-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1- methyl piperidinium

[44]

Iodide of cis-1 - [[5- (5-chloro-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[Four. Five]

Iodide of trans-1 - [[5- (5-chloro-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazole-3-carbo- nil] -amino] -1-methyl-piperidinium

[46]

Iodide of cis-1 - [[5- (5-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1H-pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[47]

Iodide of trans-1 - [[5- (5-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[48]

Iodide of cis-1 - [[5- (4-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium

[49]

Iodide of trans-1 - [[5- (4-bromo-thiophen-2-yl) -1- (2,4-dichloro-phenyl) -4-methyl-4,5-dihydro-1 H -pyrazol-3-carbonyl] -amino] -1-methyl-piperidinium Y

[fifty]

Iodide of cis-1 - [[5- (4-bromo-thiophene-2-yl) -1- (2,4-dichloro-phenyl) -4-hydroxy-4-methyl-4,5-dihydro-1H-pyrazole- 3-carbonyl] -amino] -1-methyl-piperidinium

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ newpage
      

15. N-oxide of general formula Ia, 63 at that X a is O or S; R 1a and R 2a, independently between yes, they represent in each case an aryl or heteroaryl radical, no substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted; or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, not substituted or at least monosubstituted and / or may be linked with a bridge by at least one unsubstituted alkylene group or at less monosubstituted; R 3a and R 4a, independently between yes, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H; a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted; a saturated or unsaturated cycloaliphatic radical, not substituted or at least monosubstituted, which contains optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted; an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a system cyclic mono or polycyclic, unsubstituted or at least monosubstituted and / or it can be linked through an alkylene group, a group alkenylene or an alkynylene group optionally at least monosubstituted; a moiety -O-R 7a; a rest -S-R 8a; a moiety -NH-R9a or a moiety -NR 10a R 11a; R 5a and R 6a, independently between yes, they represent in each case a hydrogen atom; a saturated or unsaturated aliphatic radical, not substituted or at least monosubstituted; or R 5a and R 6a together with the atom of bridging nitrogen form a heterocyclic ring not substituted or at least monosubstituted, saturated or unsaturated, which may contain at least one additional heteroatom as a member of ring and / or that may be condensed with one or two systems monocyclic or polycyclic, optionally at least monosubstituted; R 7a, R 8a, R 9a, R 10a and R 11a, independently of each other, represents in each case a saturated or unsaturated aliphatic radical, unsubstituted or at least monosubstituted, or a saturated cycloaliphatic radical or unsaturated, unsubstituted or at least monosubstituted, containing optionally at least one heteroatom as a ring member, which it can be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or may be attached to through an alkylene group, an alkenylene group or a group alkynylene, unsubstituted or at least monosubstituted and / or may be linked to a bridge by at least one alkylene group not substituted or at least monosubstituted; or an aryl or heteroaryl radical, unsubstituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a group alkylene, an alkenylene group or an alkynylene group, not substituted or at least monosubstituted; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same. 16. N-oxide according to claim 15, characterized in that X a is O or S; R 1a and R 2a, independently between yes, they represent in each case an aryl radical of 6 or 10 members no  substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted; a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted; a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted; or a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be joined by a bridge by at least one C 1-5 alkylene group unsubstituted or at least monosubstituted; R 3a and R 4a, independently between yes, they represent in each case H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (= O) -H; a C 1-16 alkyl radical, a C 2-16 alkenyl radical or a radical C 2-16 alkynyl unsubstituted or at least monosubstituted; a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or that can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C 2-5, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through at least one group C 1-5 alkylene unsubstituted or at least monosubstituted; a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted; an aryl radical of 6 or 10 members, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at less monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted; a 5-14 membered heteroaryl radical, not substituted or at least monosubstituted, which may be condensed with a mono or polycyclic cyclic system, unsubstituted or at least monosubstituted and / or can be linked through a group C 1-5 alkylene, alkenylene group C 2-5 or alkynylene group C 2-5 unsubstituted or at least monosubstituted; a moiety -O-R 7a; a residue-S-R 8a; a rest -NH-R 9a or a -NR 10a R 11a moiety; R 5a and R 6a, independently between yes, they represent in each case a hydrogen atom; a C 1-16 alkyl radical, C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted; or R 5a and R 6a together with the bridging nitrogen atom form a heterocyclic ring of 4 to 10 unsubstituted or at least substituted, saturated or unsaturated members, which may optionally contain 1, 2 or 3 heteroatta -
additional mo (s) selected from the group consisting of sulfur, nitrogen and oxygen as ring member (s) and / or that may be condensed with one or two monocyclic or polycyclic cyclic systems, optionally at least monosubstituted ; R 7a, R 8a, R 9a, R 10a and R 11a independently of each other, represent in each case a C 1-6 alkyl radical, a C 2-16 alkenyl radical or alkynyl radical C 2-16 unsubstituted or at least monosubstituted; a cycloalkyl radical C 3-16 or a cycloalkenyl radical C_ {4-16} unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted; a heterocycloalkyl radical C 4-16 or a heterocycloalkenyl radical C 5-16 unsubstituted or at least monosubstituted, which, in each case, may be condensed with a cyclic system mono or polycyclic, unsubstituted or at least monosubstituted and / or that can be linked by a C 1-5 alkylene group, a C 2-5 alkenylene group or a group C 2-5 alkynylene, unsubstituted or at least monosubstituted, and / or that can be joined by a bridge through the minus an unsubstituted C 1-5 alkylene group or at least monosubstituted; an aryl radical of 6 or 10 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at least monosubstituted, and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted; or a heteroaryl radical of 5 to 14 members not substituted or at least monosubstituted, which may be condensed with a cyclic, mono or polycyclic system, unsubstituted or at less monosubstituted and / or can be linked by an alkylene group C_ {1-5}, an alkenylene group C 2-5 or an alkynylene group C_ {2-5}, unsubstituted or at least monosubstituted; in which the rings of the cyclic system mentioned previously they are, in each case independently of each other, of 5, 6 or 7 members and may, in each case independently of each other, optionally contain 1, 2 or 3 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur; the heteroaryl radicals mentioned previously, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected regardless of group consisting of nitrogen, oxygen and sulfur as ring member (s); heterocycloalkyl radicals and radicals heterocycloalkenyl mentioned above, in each case, optionally contain 1, 2, 3 or 4 heteroatom (s) selected (s) regardless of the group consisting of nitrogen, oxygen and sulfur as ring member (s); optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

17. N-oxide according to claim 15 or 16, characterized in that X a is O or S; R 1a and R 2a, independently of each other, represent in each case a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl), pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridazinyl, indolyl, isoindolyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, benzo [b] furanyl, benzo [b] thiophenyl, benzo [2,1,3], benzo [2,1,3], benzo [2,1,3] [1,2,3] -benzothiadiazolyl, [2,1,3] -benzoxadiazolyl, [1,2,3] -benzoxadiazolyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl and imidazo [2,1-b] thiazolyl, which may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected
regardless of the group consisting of -CF 3, -CH 2 -Cl, -O-CH 3, -O-C 2 H 5, -O-CH 2 -CH_ { 2 -CH 3, -O-CH (CH 3) 2,
-O-CH 2 -CH 2 -CH 2 -CH 3, -OC (CH 3) 3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl, Br, I, -CN, -OCF 3, -SCF 3, -SCF 2 H, -SCFH2, -OH, -SH, -NO2, -CHO, -CF2H, -CFH2,
phenoxy and thiophenyl, in which the thiophenyl radical may be substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, methyl, ethyl and n-propyl; R 3a represents H; F; Cl; Br; I; -CN; -NO2; -NC; -OH; -NH2; -SH; -C (O) -H; a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl; a radical selected from the group consisting in phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and pyrrolyl, which may be linked through a group - (CH2) and / or may be optionally substituted with 1, 2, 3, 4 or 5 substituent (s) selected regardless of the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, -O-CH 3, -O-C 2 H 5, F, Cl and Br; a moiety -O-R 7a; a rest -S-R 8a, a moiety -NH-R 9a or a moiety -NR 10a R 11a; R 4a represents H or an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl; R 7a, R 8a, R 9a, R 10a and R 11a independently of each other, represent in each case a radical selected from the group consisting in methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl; R 5a and R 6a together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of 64

         \ vskip1.000000 \ baselineskip
      

65

         \ vskip1.000000 \ baselineskip
      

66

         \ vskip1.000000 \ baselineskip
      

67

         \ vskip1.000000 \ baselineskip
      

68 69 optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

18. Salt according to one or more of claims 15 to 17, characterized in that X a is O; R 1a represents a radical selected from the group consisting of phenyl and thienyl (thiophenyl), which may be  optionally substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br, I, -O-CH 3 and -O-C 2 H 5; R2 represents a phenyl radical, which can be substituted with 1, 2 or 3 substituent (s) selected (s) regardless of the group consisting of F, Cl, Br and I; R 3a represents H; F; Cl; Br; I; -OH, -CN; -C (= O) -H; a radical selected from the group consisting in methyl, -CF 3, -CH 2 F, -CF 2 H, -C 2 F 5, ethyl, -CH2 -CN, -CH2 -OH, n-propyl, isopropyl, -CH 2 -CH 2 -CN, -CH2 -CH2 -OH, n-butyl, -CH 2 -CH 2 -CH 2 -CN, -CH2 -CH2 -CH2 -OH, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, 2-hexyl and 3-hexyl; a benzyl radical or a residue -O-R 7; R 4a represents H or a selected radical from the group consisting of methyl, ethyl, n-propyl, iso-propyl and n-butyl; R 5a and R 6a together with the atom of nitrogen that forms a bridge form a remainder selected from the group consisting of 70 71 72 and R 7a represents a radical selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

19. N-oxide according to one or more of the claims 15 to 18 selected from the group consisting in:

[51]

N-oxide acid piperidin-1-ylamide 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1 H -pyrazol-3-carboxylic acid;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixing, or a corresponding solvate of the same.

         \ vskip1.000000 \ baselineskip
      

20. Process for the preparation of a salt of general formula I according to one or more of claims 1 to 14, wherein R 4 represents hydrogen, characterized in that at least one compound of general formula R 1 - C (= O) -H (general formula II), wherein R 1 has the meaning according to one or more of claims 1 to 14, is reacted with at least one compound of general formula III,

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

73

         \ vskip1.000000 \ baselineskip
      

in which R3 and X have the meaning according to one or more of claims 1 to 14 and R ' represents a linear C 1-6 alkyl radical or branched, a potassium cation or a sodium cation, in a medium of reaction, optionally in an inert atmosphere, optionally in presence of at least one base, to give at least one compound of General Formula IV,

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

74

         \ vskip1.000000 \ baselineskip
      

in which R 1, X and R 3 they have the meaning according to one or more of claims 1 to 14, which is optionally purified and / or isolates, and at least one compound of general formula IV is reacts with at least one compound of general formula V,

         \ vskip1.000000 \ baselineskip
      

75

         \ newpage
      

or a corresponding salt of the themselves, in which R2 has the meaning according to one or more of claims 1 to 14, in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one acid, to give at least one compound of formula general SAW, 76 in which R1, X, R2 and R 3 have the meaning according to one or more of the claims 1 to 14, which is optionally isolated and / or purify, and at least one compound of general formula VI is reacts with activating agent in a reaction medium, optionally in an inert atmosphere, to give at least one compound of general formula VII, 77 in which R1, X, R2 and R 3 have the meaning according to one or more of the claims 1 to 14 and LG represents a leaving group, which optionally purified and / or isolates, and at least one compound of general formula VII it is reacted with at least one compound of general formula NH 2 -NR 5 R 6, in which R 5 and R 6 have the meaning according to one or more of the claims 1 to 14, in a reaction medium, optionally in an inert atmosphere, optionally in the presence of at least one base selected from the group consisting of diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine and N-methylmorpholine, to give at least one compound of general formula VIII, 78 in which R 1, R 2, R 3, X, R 5 and R 6 have the meaning according to one or more of claims 1 to 14, which is optionally purified and / or be isolates or at least one compound of general formula VI is reacts with at least one compound of general formula NH 2 -NR 5 R 6, in which R 5 and R 6 have the meaning according to one or more of the claims 1 to 14, in a reaction medium, in the presence of at least one coupling agent, optionally in the presence of at least one base, to give at least one compound of general formula  VIII, which is optionally purified and / or isolated; and at least one compound of general formula VIII it is reacted with at least one compound of general formula A-B, in which A and B have the meaning according to one or more of claims 1 to 14, in a reaction medium, to give at least one salt of general formula I,

         \ vskip1.000000 \ baselineskip
      

79

         \ vskip1.000000 \ baselineskip
      

wherein A, B, R 1, R 2, R 3, X, R 5 and R 6 have the meaning according to one or more of the claims 1 to 14 and R 4 represents hydrogen, which optionally it is purified and / or isolated. 21. Medication comprising at least one salt according to one or more of claims 1 to 19 and optionally to less a physiologically acceptable auxiliary agent. 22. Medication according to claim 21 for modulation of cannabinoid receptors, preferably cannabinoid 1 (CB1) receptors, for prophylaxis and / or treatment of central nervous system disorders, disorders of the immune system, disorders of the cardiovascular system, endocrine system disorders, system disorders respiratory, gastrointestinal tract disorders or disorders players. 23. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of disorders of the food intake, preferably bulimia, anorexia, cachexia, obesity and / or diabetes mellitus type II (diabetes mellitus not insulin dependent), more preferably obesity. 24. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of psychosis. 25. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of alcoholism and / or the alcohol addiction, nicotine abuse and / or smoking, abuse of drugs and / or drug addiction and / or drug abuse and / or Drug dependence, preferably drug abuse and / or drug addiction and / or nicotine abuse and / or smoking. 26. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, cancer pancreas, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of colon cancer, intestinal cancer and cancer of prostate. 27. Medication according to claim 21 or 22 for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (for example, associated osteoporosis with a genetic predisposition, sex hormone deficit or aging), bone disease associated with cancer or disease Paget's bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, disorders spinocerebellar, cognitive disorders, head trauma, head trauma, stroke, seizures panic, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremors, disorders compulsive, senile dementia, thymic disorders, tardive dyskinesia,  bipolar disorders, movement disorders induced by medications, dystonia, endotoxémic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclera, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic pain relievers, or to influence the intestinal transit. 28. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the modulation of cannabinoid receptors, preferably cannabinoid 1 receptors (CB1), for prophylaxis and / or treatment of nervous system disorders central, immune system disorders, system disorders cardiovascular, endocrine system disorders, disorders of the respiratory system, gastrointestinal tract disorders or reproductive disorders 29. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the prophylaxis and / or treatment of ingestion disorders of food, preferably bulimia, anorexia, cachexia, obesity and / or type II diabetes mellitus (diabetes mellitus no insulin dependent), more preferably obesity. 30. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the prophylaxis and / or treatment of psychosis. 31. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the prophylaxis and / or treatment of alcoholism and / or the alcohol addiction, nicotine abuse and / or smoking, abuse of drugs and / or drug addiction and / or drug abuse and / or Drug dependence, preferably drug abuse and / or drug addiction and / or abuse of nicotine and / or smoking. 32. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, cancer pancreas, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of colon cancer, intestinal cancer and cancer of prostate. 33. Use of at least one salt according to one or more of claims 1 to 19 for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (for example, associated osteoporosis with a genetic predisposition, sex hormone deficit or aging), bone disease associated with cancer or disease Paget's bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, disorders spinocerebellar, cognitive disorders, head trauma, head trauma, stroke, seizures panic, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremors, disorders compulsive, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, movement disorders induced by medications, dystonia, endotoxémic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclera, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic pain relievers, or to influence the intestinal transit.